



Studies toward Total Synthesis of (\pm)-Caldaphnidine C via One-Pot Sequential Intramolecular Vilsmeier–Haack and Azomethine Ylide 1,3-Dipolar Cycloaddition

Jonathan Boudreault, François Lévesque, and Guillaume Bélanger*

Département de Chimie, Université de Sherbrooke, 2500 boulevard Université, Sherbrooke, Québec, J1K 2R1, Canada

 Supporting Information

ABSTRACT: An application of a one-pot sequential Vilsmeier–Haack cyclization and intramolecular azomethine ylide 1,3-dipolar cycloaddition toward the total synthesis of (\pm)-caldaphnidine C is presented. It allowed an efficient formation of three cycles with perfect control of four of the five newly created stereogenic centers including one all-carbon quaternary center. Two synthetic strategies to produce the key-step precursor, the investigation and optimization of the cyclization partners (nucleophile, azomethine ylide, and dipolarophile), and further derivatization of the cycloadduct are reported.



INTRODUCTION

Some of the most architecturally complex and synthetically challenging alkaloid natural products are found in the *Daphniphyllum* family.¹ Several impressive syntheses of many members of the 14 different types of *Daphniphyllum* alkaloids have been reported over the years,² but daphnilactone B-type and yuzurimine-type alkaloids still resist the efforts of synthetic chemists. These alkaloids share the same rigid and compact tetracyclic core **1** that could be regarded as a common synthetic intermediate to many alkaloids of these types (Figure 1).

So far, only five research groups have reported synthetic approaches toward members of daphnilactone B-type and yuzurimine-type alkaloids.³ The group of Denmark used a cascade of intramolecular hetero-Diels–Alder and nitronate cycloadditions approach, followed by reductive amination to assemble the tricyclic core **4** of these alkaloids in 27 steps (Scheme 1, top left).⁴ It should be noted that this approach is nonracemic and that the two contiguous quaternary centers (C3 and C4) were set in the key step. Hayakawa and Kigoshi reported last year a radical cyclization with compound **6** to set the tetracyclic core **7** of yuzurimine-type alkaloids (Scheme 1, bottom left).⁵ In a model study, the group of Coldham used a cascade of condensation of aldehyde **8** with ethyl glycinate, intramolecular imine alkylation, and azomethine ylide cycloaddition to build the bridged bicyclic portion **9** of the natural products (Scheme 1, top right).⁶ Through a Dieckman cyclization and decarboxylation sequence, the group of Hanessian assembled the seven-membered ring and completed four of the five cycles of daphnilactone B-type alkaloids from compound **10** (Scheme 1, middle right).⁷ Finally, our group developed one-pot sequential cyclizations to access four of the five rings common to daphnilactone B-type and yuzurimine-type alkaloids (see **13**, Scheme 1, bottom right).⁸ Herein, we

report a full account of this synthetic approach, with an extensive study of the key step, as well as our efforts to install proper functionalization on the polycyclic adduct in a premise to the completion of the total synthesis of caldaphnidine C.

RESULTS AND DISCUSSION

We embarked on this journey with the goal to prepare the common intermediate **1** depicted in Figure 1 that should allow the synthesis of both daphnilactone B-type and yuzurimine-type *Daphniphyllum* alkaloids. We felt that this common intermediate could be accessed using a new synthetic strategy we developed in our group,⁹ namely, a sequential Vilsmeier–Haack cyclization and intramolecular azomethine ylide 1,3-dipolar cycloaddition as shown in Scheme 2. This one-pot process allows the formation of three cycles of the tetracyclic core, with perfect control of four of the five newly generated stereogenic centers, the fifth one being destroyed later on. Additionally, adduct **1** bears proper functional groups to further advance toward the targeted alkaloids. The substrate for the key transformation is a cycloheptane ring **14** bearing an amide branch, a nucleophilic (Nü) alkene, and a dipolarophile branch (alkene).

We anticipated several challenges with this approach. First, the seven-membered ring key-step substrate **14** requires a *cis* relationship between the amide and the dipolarophile branches, which may be hard to control on conformationally flexible seven-membered rings (Scheme 2). Secondly, with such a densely functionalized substrate, chemoselectivity in the amide activation, as well as for all ensuing steps, could rapidly become

Received: July 28, 2016

Published: September 19, 2016






Figure 1. Representative daphnilactone B-type and yuzurimine-type *Daphniphyllum* alkaloids.

Scheme 2. Key Step and Challenges toward Common Intermediate 1



an issue. Thirdly, the transition state for the Vilsmeier–Haack cyclization is a chairlike conformation with three of the four substituents on the chair axially oriented. We could, therefore, anticipate a low concentration of the reactive conformation, usually translated in a low reaction rate and ultimately in low yield. This raised the question about the stability of triflyliminium ion **15** in these conditions. Fourthly, the


Scheme 1. Efforts toward the Total Synthesis of Daphnilactone B-Type and Yuzurimine-Type *Daphniphyllum* Alkaloids



Vilsmeier–Haack cyclization will generate a congested quaternary center (C1), adjacent to another quaternary center (C14). Fifthly, after the generation of the azomethine ylide **17**, the intramolecular 1,3-dipolar cycloaddition will create a bridged system with three new stereogenic centers. Regio- and diastereoselectivity will be controlled mainly by conformational restrictions imposed by the intramolecularity of the process. To maximize our chances of success in using this key transformation for the synthesis of daphnilactone B-type and yuzurimine-type alkaloids, we addressed each of these challenges separately with model systems.

First Model Study: Generation of a Quaternary Center in the Vilsmeier–Haack Cyclization. As an initial study, we decided to concentrate our efforts on the generation of the quaternary center in the Vilsmeier–Haack cyclization (Scheme 3). We opted to design a model compound **20** lacking the

Scheme 3. Retrosynthetic Analysis of Model Compound **18**




quaternary center at C14 and functionalization on the amide to prepare the azomethine ylide. We hoped to confirm this first step in the sequence after reduction of the transient iminium ion **19**. The key-step precursor **20** would be obtained after the


installation of an allylsilane, the nucleophile chosen for this first study. Side chains would be incorporated on cycloheptanone in a *cis* relationship through 1,4-addition and alkylation reactions.

The synthesis of compound **20** started with the transesterification of known methyl ester **22** using allyl alcohol (Scheme 4).¹⁰ After alkylation with 4-bromobutene, treatment of allyl β -ketoester **24** in oxidative deallyloxyacylation conditions¹¹ using $\text{Pd}_2(\text{dba})_3$ generated a 1:1 mixture of *endo* and *exo* enones **25** and **26**, respectively. Fortunately, careful separation of these isomers led to the isolation of pure *endo* enone **25** that was used in the next steps. A Mukaiyama–Michael addition of silyl ketene acetal **27**¹² in the presence of TiCl_4 ,¹³ followed by kinetic protonation of the resulting enolate at low temperature with acetic acid, produced a 3.4:1 mixture of two hardly separable diastereomers **28** and **29**. Unfortunately, we have not been able to prove the relative stereochemistry beyond any doubt,¹⁴ but related examples in the literature on five- and six-membered rings present a good selectivity for *cis* isomers.¹² One-pot addition of vinylmagnesium bromide to ketone, trapping of the resulting alcoholate with ethyl chloroformate, and $\text{S}_{\text{N}}2'$ displacement of the allylcarbonate with silyl organocuprate $(\text{PhMe}_2\text{Si})_2\text{CuCNLi}_2$ gave allylsilane **29** in good yield. Only the major diastereomer **28** reacted in these conditions. Saponification of *tert*-butyl ester **30**, followed by Curtius rearrangement,¹⁵ reduction of the resulting isocyanate,¹⁶ and formylation using Katritzky reagent, *N*-formylbenzotriazole,¹⁷ furnished compound **20** in 71% yield over four steps.

At this point, installation of the quaternary center and preparation of the bridged azabicyclo[4.3.1]decane unit **18** using the intramolecular Vilsmeier–Haack cyclization was tested (Scheme 5). We planned to reduce the iminium ion **19** *in situ* to be able to isolate and characterize the product. Although the activation of formamide **20** with triflic anhydride in the presence of 2,6-di-*t*-butyl-4-methylpyridine (DTBMP) gave triflyliminium ion **32**, no cyclization was observed at room temperature. Pushing the conditions to refluxing 1,2-dichloro-


Scheme 4. Synthesis of the Vilsmeier–Haack Cyclization Precursor **20** with Allylsilane



Scheme 5. Vilsmeier–Haack Cyclization with Allylsilane **20**


ethane (DCE) resulted in a quite unusual cyclization: after iminium reduction, cycloadduct **35** was obtained, corresponding to an unexpected regioselectivity for the reaction of the allylsilane. Facing the steric constraint due to the generation of the quaternary center in the anticipated adduct **19**, the allylsilane reacted with the least nucleophilic site (β to Si) to generate a tertiary center as in **33**. This result convinced us that the allylsilane was not nucleophilic enough for the Vilsmeier–Haack cyclization on substrate **20** and stronger carbon nucleophiles are needed in order to force the generation of the hindered quaternary carbon.

The choice of a silyl enol ether as a stronger nucleophile was obvious.¹⁸ Installation of the latter was performed on a mixture of ketones **28** and **29** synthesized in the first model study. Hence, a Wittig olefination afforded methyl enol ether **36** (Scheme 6).¹⁹ Unlike the case for the installation of the allylsilane, this time, both diastereomers **28** and **29** reacted and a mixture of four partially separable isomers of **36** was obtained. The next steps up to compound **38** followed the sequence previously developed. Hydrolysis of methyl enol ether **38**,^{20,21}

Scheme 6. Synthesis of the Vilsmeier–Haack Cyclization Precursor **40** with Silyl Enol Ether

followed by enolization of aldehyde **39** with *tert*-butyldimethylsilyl trifluoromethanesulfonate (TBDMSOTf), afforded silyl enol ether **40**.^{22,23}


Upon activation of formamide **40** with triflic anhydride, the intramolecular Vilsmeier–Haack reaction proceeded smoothly at room temperature over 18 h. Triflyliminium ion **41** can even be observed by ¹H NMR considering the slow rate of the cyclization, and refluxing conditions were necessary to get a complete conversion to iminium ion **42** (Scheme 7). The latter

Scheme 7. Vilsmeier–Haack Cyclization with Silyl Enol Ether **40**

was reduced *in situ* with NaBH₄ to provide bicyclic compound **43** in an unoptimized 48% yield. Surprisingly, the aldehyde was not reduced. This result definitely confirmed the possibility to create a quaternary center during the formation of the piperidine ring using a silyl enol ether as the nucleophile in the intramolecular Vilsmeier–Haack reaction.


Second Model Study: Preparation of the Azomethine Ylide and Intramolecular 1,3-Dipolar Cycloaddition. The next objective of this study was to evaluate the feasibility of the second cyclization, a 1,3-dipolar cycloaddition. The most direct route to daphnilactone B congeners was to opt for an unstabilized azomethine ylide ($R'' = \text{SiMe}_3$ or SnBu_3 , Scheme 2) as a dipole since the latter leads to a methylene β to nitrogen in the pyrrolidine ring, as in the natural products.²⁴ As shown in Scheme 8, a Curtius rearrangement on the previously synthesized carboxylic acid **37** and treatment of the resulting isocyanate with 9-fluorenylmethanol in the presence of $\text{Ti}(\text{O}-t\text{-Bu})_4$ furnished *N*-Fmoc protected amine **44** in good yield (92% over 3 steps).²⁵ Formamide **45** was obtained following deprotection of the Fmoc group with NaH, *in situ* alkylation

Scheme 8. Synthesis of Cyclization Precursor 47 with Silyl Enol Ether



of the sodium amide with iodomethyltrimethylsilane, and formylation¹⁷ in 60% overall yield. Hydrolysis of the methyl enol ether 45 was more problematic, and previous conditions (2 N HCl) failed probably due to the sensitivity of the trimethylsilyl group to acidic conditions and to chloride anions. Diluted aqueous trichloroacetic acid worked best, and aldehyde 46 was obtained in good yield (82%).²⁶ Finally, enolization²² of the latter furnished the compound 47 that was then tested in the full cyclization sequence.

Scheme 9. Attempted Key Sequential Cyclizations with Silyl Enol Ether 47




Formamide 47 was activated with triflic anhydride in the presence of DTBMP, and after 3 h at $50\text{ }^\circ\text{C}$, a complete Vilsmeier–Haack cyclization was observed by ^1H NMR (Scheme 9). However, when a source chloride was added to *N*-trimethylsilylmethyliminium ion 49 to promote desilylation and generation of the unstabilized azomethine ylide 50, no cycloadduct 51 was obtained. To verify the formation and reactivity of azomethine ylide 50, addition of an excess of an external dipolarophile such as dimethyl acetylenedicarboxylate (DMAD) or *N*-phenylmaleimide, using tetrabutylammonium chloride (TBAC) or tetrabutylammonium triphenyldifluoro-silicate (TBAT) to promote desilylation also failed to produce the expected cycloadducts 54 or 55, respectively. In all cases, only aldehyde 46 was recovered after workup. We postulated that there was a reversible addition of halide to the iminium ion 49 which resulted in a retro-Mannich reaction, thus releasing ring strain in the bridged bicyclic system of 52, to produce aldehyde 46 as the sole isolated product.

At this point, two possible solutions were envisaged to circumvent this reactivity issue and favor conversion of the cascade precursor to the desired tetracyclic adduct. The first one was to weaken the carbon–metal bond in compound 47 by replacing silicon with tin.^{9b,27} This way, the demetalation rate should increase²⁸ and the desired azomethine ylide 50 may be formed and trapped prior to any addition to the iminium ion and retro-Mannich reaction. Unfortunately, the carbon–tin bond is too labile and incorporation of a stannane at different points in the synthesis never led to the desired tin-containing key-step precursor.

The second solution was to avoid the use of a nucleophile to generate the azomethine ylide. Instead, the latter would be prepared by deprotonation α to the iminium nitrogen on a substrate bearing an electron-withdrawing group (cf. 49, Me_3Si = nitrile or ester). However, additional steps are expected to cleave off this electron-withdrawing group after the cycloaddition since no substitution is present in the natural products on methylene β to nitrogen in the pyrrolidine ring. As shown in Scheme 10, installation of a nitrile group was performed on


intermediate **44** and the same subsequent reaction sequence was applied.

Scheme 10. Synthesis of Cyclization Precursor **59** with a Nitrile



Formamide **59** was treated with triflic anhydride, and formation of triflyliminium ion **60** was confirmed by ^1H NMR (Scheme 11). Hunig's base ($i\text{-Pr}_2\text{NEt}$) was then added to generate the corresponding stabilized azomethine ylide, but the desired cycloadduct **61** was observed only in traces by ^1H NMR spectrometry on the crude material. This result may be explained by one or more of the following three plausible


Scheme 11. Attempted Key Sequential Cyclizations with Silyl Enol Ether-Nitrile **59**



hypotheses. (1) The nitrile was not compatible with the activation conditions. (2) The major isomer obtained from the 1,4-addition of silyl ketene acetal **27** to heptenone **25**, followed by a kinetic protonation (Scheme 4), was not the *cis* isomer **28** leading to **59** as expected but rather the *trans* product **29** leading to **62** (Scheme 11). The latter could not undergo intramolecular cycloaddition because the butenyl side chain would point in the wrong direction (cf. **63**). (3) The terminal alkene was not activated enough to react with the stabilized azomethine ylide.²⁹

Compatibility of the nitrile in the key cyclization sequence was tested on model substrate **65** prepared straightforwardly from known formamide **64** (Scheme 12).^{9a} Alkylation with


Scheme 12. Synthesis and Key Sequential Cyclizations with Model Substrate **65**



bromoacetonitrile was not optimal but nonetheless furnished enough material to test our hypothesis. Iminium **66** was observed after treatment of formamide **65** with triflic anhydride without affecting the nitrile group. The ensuing azomethine ylide formation and 1,3-dipolar cycloaddition with *N*-phenylmaleimide produced cycloadduct **67** in good yield (69%) as a mixture of four diastereomers. Compatibility of the nitrile group in this sequence of cyclization was thus demonstrated, and the unsuccessful key sequential cyclizations of Scheme 11 could only be explained by the wrong *trans* diastereomer (cf. **62**) and/or the lack of reactivity of the terminal alkene in the cycloaddition.

To address both of these issues, a completely new synthesis of the key reaction substrate was designed. The route will unequivocally establish the correct and needed relative stereochemistry between the amide and the dipolarophile. It will also allow modulation of the dipolarophile reactivity: according to the work of Coldham, a dramatic increase in reactivity (lower temperature and higher yield) is observed for stabilized azomethine ylide cycloadditions when an ester-substituted alkene is used as the dipolarophile instead of a nonsubstituted terminal alkene.²⁹

Third Model Study: Preparation of an Azomethine Ylide Stabilized with an Ester and Evaluation of Intramolecular 1,3-Dipolar Cycloaddition. To better control the relative stereochemistry on cycloheptane **69**, we envisaged the preparation of the substituted seven-membered ring using a ring-closing metathesis on diene **71** (Scheme 13). The latter would be obtained from a Claisen rearrangement of allyl enol ether **72**. Relative stereochemistry would be secured by a diastereocontrolled alkylation of the five-membered


Scheme 13. Retrosynthetic Analysis for the Core of Daphnilactone B-Type and Yuzurimine-Type *Daphniphyllum* Alkaloids


lactone **73**.³⁰ This new approach also ensures a certain variation of the dipolarophile since it is installed last in the sequence (**70** to **69**).


This new synthesis started with a sequence we already published.³¹ Formamide was alkylated with bromide **75**, but a large amount of the elimination product **77** was observed (Scheme 14). To avoid this problem, a less basic nucleophile was necessary. Alkylation of sodium formimide, followed by hydrolysis, produced the desired amide **76** in good yield (78%) with no elimination side product.³² Due to a complicated alkylation of formamide **64** with bromoacetonitrile (Scheme 12) in the model study, we chose to install an ester instead of a nitrile as an electron-withdrawing group. Alkylation of

formamide **76** with ethyl bromoacetate generated compound **78**, which was then heated to induce the Claisen rearrangement³³ that quantitatively furnished diene **79** (Scheme 14). The latter was subjected to ring-closing metathesis with the second-generation Grubbs' catalyst,³⁴ and the resulting aldehyde **80** was silylated. Finally, benzyl ether deprotection, Swern oxidation of alcohol **82**, and olefination of the resulting aldehyde using Still–Gennari conditions³⁵ gave the key-step precursor **83**.


Unfortunately, upon activation of formamide **83** with triflic anhydride in the presence of DTBMP, no Vilsmeier–Haack cyclization product **85** was observed (Scheme 15). ¹H NMR

Scheme 15. Attempted Key Sequential Cyclizations with Silyl Enol Ether **83**


analysis showed a fast protonation of the base (DTBMP) and signals corresponding to an oxazolium ion **86** that could be generated after the formation of triflyliminium ion **84**. Oxazolium ion **86** was not electrophilic enough to be trapped

Scheme 14. Synthesis of the Cyclization Precursor **83**


Scheme 16. Synthesis of the Cyclization Precursor 92 with Two Different Approaches



with the internal silyl enol ether despite heating to reflux.³⁶ Hence, we decided to reinvestigate the installation of a nitrile as an electron-withdrawing group to avoid this problem.


Fourth Model Study: Preparation of an Azomethine Ylide Stabilized with a Nitrile and Intramolecular 1,3-Dipolar Cycloaddition. Installation of the cyanomethyl onto the formamide is always low yielding, presumably because of proton exchange between formamide anion, bromoacetonitrile, and/or the alkylated *N*-(cyanomethyl)formamide. Alkylation of the primary amine prior to formylation seemed to be more promising. Moreover, because we had in the past some enol ether hydrolysis issues, we designed two similar routes to prepare either the silyl enol ether or the dipolarophile in the last steps (approaches A and B, respectively, Scheme 16). Both approaches start with bromide displacement with ammonia,³⁷ followed by alkylation with bromoacetonitrile, then formylation. This sequence is performed on benzyl ether 75 in approach A, or on free alcohol 93 in approach B without affecting the hydroxyl group.

In the approach A, a Claisen rearrangement on compound 87, followed by a ring-closing metathesis, allowed us to incorporate the silyl enol ether group on aldehyde 89 prior to the dipolarophile. Deprotection of benzyl ether 90 was not as

easy as in the sequence presented in Scheme 15 (cf. 75 to 77).³⁸ The nitrile group on 90 interfered with the hydrogenolysis of the benzyl group (Scheme 16). We found that conditions using Guindon's reagent worked best to smoothly cleave the benzyl group while preserving the nitrile, the formamide, and even the very sensitive silyl enol ether.³⁹ Interestingly, these conditions allowed keeping the endocyclic alkene in place, which could later be used to incorporate the cyclopentene ring present in the natural products. Finally, oxidation of alcohol 91 and olefination installed the dipolarophile in moderate yields (47% over two steps).


In the approach B, alcohol 94 was oxidized and olefinated in a much better yield (76%, two steps). A Claisen rearrangement and ring-closing metathesis furnished aldehyde 96.⁴⁰ The sequence ended with a silylation to generate the cyclization precursor 92, albeit in moderate yield (40%). These two approaches count 9–10 steps from intermediate 75 and gave similar overall yields (8–10%).

We were finally pleased to find out that activation of formamide 92 with triflic anhydride allowed a clean Vilsmeier–Haack cyclization at room temperature in less than 5 min (Scheme 17). Iminium ion 97 was then deprotonated with *i*-Pr₂NEt at different temperatures (40 °C in DCE, 110 °C in

Scheme 17. Key Sequential Cyclizations with Silyl Enol Ether **92**


toluene, or 120 °C in chlorobenzene) to form the azomethine ylide that engaged in the intramolecular 1,3-dipolar cycloaddition. While higher temperatures seemed to cause degradation of the ylide, the cycloaddition smoothly occurred at room temperature to form the highly congested tetracyclic product **98** in an impressive 86% yield.

Fifth Model Study: Intramolecular 1,3-Dipolar Cycloaddition between Nitrile-Stabilized Azomethine Ylide and Methyl-Substituted Alkene. A structural analysis of daphnilactone B-type and yuzurimine-type *Daphniphyllum* alkaloids shows a methyl on the pyrrolidine ring (**1**, $\text{R}' = \text{Me}$, Figure 1) instead of an ester group (**98**, Scheme 17). A more direct access to the core of these alkaloids would involve a methyl-substituted dipolarophile (cf. **92**, $\text{CO}_2\text{Me} = \text{Me}$) even though we were aware that this dipolarophile could present a reactivity issue. As shown in Scheme 18, Swern oxidation of alcohol **94**, followed by Wittig olefination, gave the desired dipolarophile **99** with a *cis* geometry.⁴¹ The same three steps used previously in approach B (Scheme 16) furnished the key-step compound **100** (Scheme 18). It is worth mentioning that the second-generation Grubbs' catalyst for the ring-closing


Scheme 18. Synthesis of the Cyclization Precursor **102**

metathesis on substrate **100** induced a problematic isomerization of the *cis*-dipolarophile, while the first-generation Grubbs' catalyst preserved the integrity of the *cis*-alkene.⁴²


Unfortunately, after activation of formamide **102** and Vilsmeier–Haack cyclization, no cycloaddition product **104** was observed, even when the temperature was increased to 160 °C (Scheme 19). It thus seems that the dipolarophile really needs to be activated for the cycloaddition to occur.

Scheme 19. Attempted Key Sequential Cyclizations with Silyl Enol Ether **102**

Further Derivatization of the Key Tetracyclic Product. Functionalization of cycloadduct **98** was then undertaken. Homologation of the aldehyde, reduction of the methyl ester, and cleavage of the nitrile were required to advance toward caldaphnidine **C** (Figure 2).⁴³

Figure 2. Planned functionalization of cycloadduct **98**.

A Horner–Wadsworth–Emmons olefination was realized on aldehyde **98** to install the required number of carbons on this chain (Scheme 20).⁴⁴ Only the *trans*-isomer of the ester **105**

Scheme 20. Derivatization of the Key Tetracyclic Product **98**

was formed, but as a mixture of three diastereomers. Epimerization α to the methyl ester (1:1) for one of the two diastereomers of **105** in the course of the olefination explains this result. Any attempt to reductively remove the nitrile group failed (Na in NH_3 ,⁴⁵ NaBH_4 ⁴⁶ or NaBH_3CN in MeOH or MeCN, with or without Bronsted – AcOH ⁴⁷ – or Lewis – ZnBr_2 ,⁴⁸ AgBF_4 ⁴⁹ – acids). We thus decided to rather eliminate the nitrile group using NaH, and vinylogous carbamate **106** was obtained as a single diastereomer.⁵⁰ Finally, all three alkenes on **106** were hydrogenated⁵¹ and the methyl ester was reduced with LiBH_4 . Compound **107** was isolated without reduction of *tert*-butyl ester, and the relative stereochemistry at C10 was explained by hydrogenation from the convex face of this crowded cage compound.⁵²

CONCLUSION

This work establishes clearly the efficiency of one-pot sequential cyclizations to build rapidly complex architectures corresponding to the cores of natural products. The sequence of intramolecular Vilsmeier–Haack reaction and azomethine ylide 1,3-dipolar cycloaddition allowed the assembly of three new cycles in a constrained bridged system, as well as the perfect control of four of the five new stereogenic centers. The Vilsmeier–Haack cyclization successfully generated the congested quaternary center when using a reactive enol ether nucleophile. Chemoselectivity proved to be very high when a non-nucleophilic base was used to generate the stabilized azomethine ylide; otherwise, nucleophiles (such as halides used to promote desilylation to unstabilized azomethine ylides) provoked an unwanted opening of the bridged bicyclic iminium intermediate. Further functional group manipulations brought the cycloadduct to what could be seen as the closest to the natural products in the daphnilactone B-type and yuzurimine-type *Daphniphyllum* family so far reported. Future work will address the design of a nonracemic route and the installation of the required additional quaternary center (see **1**, C14) at the ring junction of the six- and seven-membered rings, as well as the installation of the cyclopentene ring on the cycloadduct.

EXPERIMENTAL SECTION

General Information. All reactions requiring anhydrous conditions were conducted in flame-dried glassware under a dry nitrogen or argon atmosphere. THF and Et_2O were distilled from Na and benzophenone under nitrogen immediately prior to use. MeCN, benzene, DCM, DCE, *i*- Pr_2NH , *i*- Pr_2NEt , and toluene were distilled from CaH_2 under nitrogen immediately prior to use. MeOH was distilled over 4 Å molecular sieves. TiF_4 and CDCl_3 were distilled over a small amount of phosphorus pentoxide (P_2O_5) under nitrogen immediately prior to use. Ethyl chloroformate and TBDMSTf were distilled under nitrogen immediately prior to use. All other required fine chemicals were used directly without purification. Thin layer chromatography (TLC) was conducted with precoated 60 Å 250 μm silica gel plates with F-254 indicator and visualized using a combination of UV and anisaldehyde, ceric ammonium molybdate, iodine on silica, or potassium permanganate staining. Flash column chromatography was performed using silica gel (230–400 mesh). Melting points are uncorrected. IR spectra were recorded with a FTIR instrument by applying substrates as thin films onto a KBr plate. ^1H and ^{13}C NMR spectra were recorded on 300 MHz and/or 400 MHz spectrometers. All chemical shifts are referenced to residual non-deuterated solvent. Data for proton spectra are reported as follows: chemical shift (multiplicity [singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint), and multiplet (m)], coupling constants [Hz], integration). Carbon spectra were recorded with complete proton decoupling, and the chemical shifts are reported in ppm.

Usual Reaction Workup and Purification. After addition of the indicated aqueous solution, layers were separated. The aqueous phase was extracted with the indicated solvent, and the combined organic phases were washed with the indicated aqueous solution (if needed), dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure using a rotary evaporator. The crude material was purified by flash chromatography using silica gel with the indicated eluent.

Allyl 2-Oxocycloheptane-1-carboxylate (23). Na^0 (small cube) was added to a solution of **22** (47 g, 0.28 mol) in allyl alcohol (300 mL) at rt. The mixture was heated to 100 °C (with a condenser) over 5 days and was allowed to cool to rt; then water was added. The usual workup (EtOAc) and purification (5% EtOAc in hexanes) afforded a mixture of **23** and its enolic form (50 g, 91%) as a colorless oil: ^1H NMR (300 MHz, CDCl_3) δ (ppm) 12.66 (s) and 3.58 (dd, $J = 10.5$, 4.0 Hz) (1H), 6.03–5.84 (m, 1H), 5.32 (d, $J = 17.0$ Hz, 1H), 5.25 (dd, $J = 10.5$, 1.0 Hz, 1H), 4.66–4.61 (m, 2H), 2.63–2.58 (m, 1H), 2.46–2.40 (m, 2H), 2.15–2.07 (m) and 1.99–1.81 (m) (2H), 1.77–1.70 (m) and 1.67–1.56 (m) (2H), 1.54–1.41 (m, 2H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 208.7, 179.9, 172.5, 170.1, 132.3, 131.7 118.3, 117.6, 101.3, 65.5, 64.8, 58.8, 43.0, 35.3, 31.9, 29.5, 27.9, 23.7, 23.4, 24.3; IR (film) ν (cm^{-1}) 2929, 2854, 1744, 1705, 1637, 1610, 1239, 1213; MS m/z (rel %) 196 (7) [M^+], 139 (26), 81 (100), 55 (99), 41 (90); HRMS (IE) calcd for $\text{C}_{11}\text{H}_{16}\text{O}_3$ 196.1099, found 196.1104.

Allyl 1-(But-3-enyl)-2-oxocycloheptane-1-carboxylate (24). NaH (60% in mineral oil, 251 mg, 6.30 mmol) was added to a solution of **23** (1.03 g, 0.52 mmol) in DMF (14 mL) at rt. The mixture was stirred 10 min at rt; then bromobut-3-ene (582 μL , 5.72 mmol) was added. The resulting mixture was stirred to 40 °C for 24 h and then was allowed to cool to rt. DMF was removed on a rotary evaporated using a mechanical pump; then water was added. The usual workup (Et_2O) and purification (2% EtOAc in hexanes) afforded **24** (1.1 g, 85%) as a colorless oil: ^1H NMR (300 MHz, CDCl_3) δ (ppm) 5.94–5.71 (m, 2H), 5.32 (d, $J = 17.0$ Hz, 1H), 5.24 (d, $J = 10.5$, 1H), 5.01 (d, $J = 18.5$ Hz, 1H), 4.95 (d, $J = 10.5$ Hz, 1H), 4.62 (d, $J = 5.0$ Hz, 2H), 2.67–2.59 (m, 1H), 2.52–2.45 (m, 1H), 2.21–1.96 (m, 4H), 1.81–1.47 (m, 8H); ^{13}C NMR (75.5 MHz, CDCl_3) δ (ppm) 208.9, 171.9, 137.8, 131.5, 118.5, 114.7, 65.4, 62.4, 41.9, 34.5, 32.7, 29.8, 28.8, 25.5, 24.7; IR (film) ν (cm^{-1}) 3078, 2932, 2860, 1737, 1710, 1453, 1201, 1148, 993, 939; MS m/z (rel %) 250 (1) [M^+], 209 (18), 196 (100), 138 (67), 84 (47); HRMS (IE) calcd for $\text{C}_{15}\text{H}_{22}\text{O}_3$ 250.1569, found 250.1576.

2-(But-3-enyl)cyclohept-2-enone (25) and 2-(But-3-enylidene)cycloheptanone (26). A solution of $\text{Pd}_2(\text{dba})_3$ (40 mg, 0.07 mmol, weighed in a glovebox) in MeCN (3 mL) was heated to reflux; then a solution of **24** (3.5 g, 14 mmol) in MeCN (3 mL) was added dropwise. After 2 h at reflux, the mixture was allowed to cool to rt and was filtered on Florisil. The solution was concentrated under reduced pressure, and the usual purification (2% Et_2O in hexanes) afforded **25** (0.98 g, 43%) and **26** (0.98 g, 43%) as colorless oils. **25:** ^1H NMR (300 MHz, CDCl_3) δ (ppm) 6.46 (t, $J = 6.5$ Hz, 1H), 5.74 (ddt, $J = 16.5$, 10.0, 6.5 Hz, 1H), 4.96 (dd, $J = 15.5$, 1.5 Hz, 1H), 4.92 (d, $J = 8.0$ Hz, 1H), 2.55 (t, $J = 6.5$ Hz, 2H), 2.38–2.29 (m, 4H), 2.12 (q, $J = 7.0$ Hz, 2H), 1.77–1.67 (m, 4H); ^{13}C NMR (75.5 MHz, CDCl_3) δ (ppm) 205.0, 142.9, 141.8, 138.1, 114.8, 42.5, 33.3, 32.4, 27.3, 25.0, 21.4; IR (film) ν (cm^{-1}) 3580–3077, 1656, 1637; MS m/z (rel %) 164 (25) [M^+], 149 (30), 135 (32), 121 (27), 107 (39), 95 (100), 79 (57), 67 (93); HRMS (IE) calcd for $\text{C}_{11}\text{H}_{16}\text{O}_1$ 164.1201, found 164.1204. **26:** ^1H NMR (300 MHz, CDCl_3) δ (ppm) 6.58 (t, $J = 7.0$ Hz, 1H), 5.81 (ddt, $J = 16.5$, 10.0, 6.0 Hz, 1H), 5.09–5.02 (m, 2H), 2.91 (t, $J = 6.0$ Hz, 2H), 2.62–2.59 (m, 2H), 2.45–2.41 (m, 2H), 1.78–1.61 (m, 6H).

***t*-Butyl syn-(2-(But-3-enyl)-3-oxocycloheptyl)acetate (28) and *t*-Butyl anti-(2-(But-3-enyl)-3-oxocycloheptyl)acetate (29).** A solution of *n*-BuLi (50.0 mL, 2.45 M in hexanes, 123 mmol) was added dropwise to a solution of *i*- Pr_2NH (20.3 mL, 143 mmol) in THF (26 mL) at 0 °C. The mixture was stirred for 15 min at 0 °C and then was cooled to –78 °C, and *t*-BuOAc (15.0 mL, 111 mmol) was added. The mixture was stirred for 3 h at –78 °C, then warmed up to –35 °C (critical), and TMSCl (16.9 mL, 134 mmol) was added. The mixture was stirred for 3 h; then a distillation

apparatus was installed directly on the reaction flask. Distillation under reduced pressure (~10–15 mmHg, fraction collected at 65–74 °C) furnished a 1.0:2.0 mixture of C-silylated product and O-silylated product **27** (15.9 g, 57%) as a colorless oil. The mixture (7.2 g, 63% pure, 24 mmol) was added to a solution of **25** (2.8 g, 17 mmol) in THF (300 mL). The mixture was cooled to –78 °C, and TiCl₄ (285 μL, 2.60 mmol) was added dropwise. The mixture was stirred for 3 h at –78 °C; then acetic acid (3.0 mL, 52 mmol) was added. The resulting mixture was stirred for 20 min; then water was added. The usual workup (DCM) and purification (DCM) afforded a hardly separable 4:1 mixture of **28** and **29** (3.59 g, 75%) as a colorless oil. A small fraction of pure compounds was obtained and characterized. **28**: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 5.75 (ddt, *J* = 17.0, 10.0, 6.5 Hz, 1H), 5.00 (d, *J* = 17.0 Hz, 1H), 4.96 (d, *J* = 7.0 Hz, 1H), 2.90–2.85 (m, 1H), 2.51 (t, *J* = 5.0 Hz) and 2.46 (t, *J* = 5.0 Hz) (1H), 2.39–2.27 (m, 2H), 2.20 (dd, *J* = 15.5, 3.5 Hz, 1H), 2.06–1.63 (m, 9H), 1.48–1.25 (m, 2H), 1.42 (s, 9H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 213.6 (s), 171.9 (s), 138.0 (d), 114.8 (t), 80.0 (s), 53.0 (d), 44.1 (t), 36.0 (d), 34.8 (t), 33.8 (t), 31.8 (t), 27.8 (q), 23.8 (t), 23.2 (t); IR (film) ν (cm⁻¹) 2976, 2930, 1728, 1699, 1146; MS *m/z* (rel %) 280 (1) [M⁺], 224 (32) [M⁺ – C₄H₈], 170 (100), 152 (44), 111 (98); HRMS calcd for C₁₇H₂₈O₃: 280.2038, found: 280.2044. **29**: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 5.75 (ddt, *J* = 17.0, 10.0, 6.5 Hz, 1H), 5.00 (d, *J* = 17.0 Hz, 1H), 4.96 (d, *J* = 7.0 Hz, 1H), 2.61 (dt, *J* = 11.5, 3.5 Hz, 1H), 2.40 (dd, *J* = 15.5, 3.5 Hz, 1H), 2.34–2.26 (m, 1H), 2.21 (dt, *J* = 10.0, 4.0 Hz, 1H), 2.13–2.05 (m, 1H), 2.03–1.76 (m, 4H), 1.74–1.52 (m, 4H), 1.49–1.42 (m, 2H), 1.45 (s, 9H), 1.27–1.78 (m, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 215.1 (s), 171.9 (s), 137.7 (d), 115.2 (t), 80.6 (s), 57.4 (d), 41.0 (t), 40.4 (t), 37.7 (d), 32.9 (t), 31.5 (t), 30.2 (d), 28.1 (q), 27.8 (t), 26.0 (t); IR (film) ν (cm⁻¹) 2978, 2931, 2854, 1728, 1703, 1367, 1250, 1151; MS *m/z* (rel %) 280 (2) [M⁺], 223 (31) [M⁺ – C₄H₈], 170 (100), 152 (38), 111 (50); HRMS calcd for C₁₇H₂₈O₃: 280.2038, found: 280.2044.

t-Butyl 2-(2-(But-3-enyl)-3-(2-(dimethylphenylsilyl)ethylidene)cycloheptyl)acetate (30). PhMe₂SiCl (8.2 mL, 49 mmol) was added to a suspension of Li⁰ (2.0 g, 290 mmol) in THF (49 mL) at 0 °C. The mixture was stirred for 18 h at 0 °C; then 39 mL of this solution was transferred to a flask containing a suspension of CuCN (1.9 g, 21 mmol, weighed in a glovebox) in THF (40 mL) at 0 °C. The mixture was stirred for 4.5 h at 0 °C. Meanwhile, in a separate flask, vinylmagnesium bromide (11 mL, 1 M in THF, 11 mmol) was added dropwise to a solution of **28** and **29** (2.0 g, 4:1 *syn: anti*, 7.1 mmol) in THF (120 mL) at rt. The mixture was stirred for 2.25 h at rt; then ClCO₂Et (1.4 mL, 18 mmol) was added. After 15 min of stirring at 0 °C, the solution was transferred via canula to the solution of silylcuprate. The resulting mixture was allowed to warm to rt over 3 h; then a saturated aqueous NH₄Cl solution was added. The usual workup (EtOAc) and purification (5% Et₂O in hexanes) afforded an inseparable mixture of *E/Z* isomers (4.0:1.0) of **30** (2.1 g, 68%; 85% based on **28** only) as a colorless oil.⁵³ ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.53–7.50 (m, 2H), 7.36–7.33 (m, 3H), 5.84–5.71 (m, 1H), 5.16 (t, *J* = 8.5 Hz, 1H), 4.98–4.90 (m, 2H), 2.25–1.78 (m, 8H), 1.74–1.60 (m, 2H), 1.58–1.17 (m, 8H), 1.43 (s, 9H), 0.29 (s) and 0.28 (s) (6H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 173.0, 139.2, 138.3, 133.6, 129.0, 127.7, 123.4, 121.6, 114.3, 79.8, 50.0, 41.5, 41.1, 40.9, 39.8, 39.8, 34.2, 32.7, 32.6, 32.3, 32.0, 28.2, 27.7, 27.2, 26.4, 25.8, 25.0, 17.7, 17.2, –3.0; IR (film) ν (cm⁻¹) 3069, 2926, 2864, 1723, 1144, 909, 734; MS *m/z* (rel %) 426 (5) [M⁺], 353 (7), 176 (14), 135 (100); HRMS calcd for C₂₇H₄₂O₂Si: 426.2954, found: 426.2950.

2-(2-(But-3-enyl)-3-(2-(dimethylphenylsilyl)ethylidene)cycloheptyl)acetic Acid (31). KOH (340 mg, 71.3 mmol) was added to a solution of **30** (2.08 g, 4.88 mmol) in a mixture of EtOH (240 mL) and water (5 mL). The resulting mixture was heated to reflux for 5 days and then allowed to cool to rt. Part of the EtOH was removed under reduced pressure on the rotary evaporator. pH was adjusted to 1 at 0 °C with 1 N H₂SO₄. The usual workup (EtOAc) and purification (5 to 50% EtOAc in hexanes) afforded an inseparable mixture of *E/Z* isomers (4.0:1.0) of **31** (1.3 g, 72%) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.55–7.52 (m, 2H), 7.37–7.35 (m, 3H), 5.79 (ddt, *J* = 17.0, 10.5, 6.5 Hz, 1H), 5.19 (t, *J* = 8.5 Hz,

1H), 4.97 (d, *J* = 17.0 Hz, 1H), 4.94 (d, *J* = 10.0 Hz, 1H), 2.44–2.25 (m), 2.19–2.11 (m), 2.07–1.82 (m), and 1.79–1.21 (m) (17H), 0.57 (s) and 0.49–0.37 (m) (1H), 0.31 (s, 6H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 180.5 (s), 139.0 (d), 137.8 (s), 133.6 (d), 129.0 (d), 127.8 (d), 123.6 (d), 121.8 (d), 114.5 (d), 49.8 (d), 41.6 (d), 40.3 (d), 38.1 (t), 34.3 (t), 32.5 (t), 32.2 (t), 32.0 (t), 28.6 (t), 28.1 (t), 27.1 (t), 26.3 (t), 25.4 (t), 24.9 (t), 17.7 (t), 17.2 (t), –3.0 (q); IR (film) ν (cm⁻¹) 3358–2511 (br), 2924, 1705, 1425, 1248, 833; MS *m/z* (rel %) 370 (4) [M⁺], 251 (8), 176 (10), 135 (100); HRMS calcd for C₂₃H₃₄O₂Si: 370.2328, found: 370.2321.

N-(2-(But-3-enyl)-3-(2-(dimethylphenylsilyl)ethylidene)cycloheptyl)methyl-N-methyl-formamide (20). ClCO₂Et (195 μL, 2.07 mmol) was added to a solution of **31** (750 mg, 2.03 mmol) and *i*-Pr₂NEt (439 μL, 2.52 mmol) in acetone (7.5 mL) at 0 °C, and the mixture was stirred for 30 min at 0 °C. Then an aqueous solution of NaN₃ (5.9 M, 690 μL, 4.08 mmol) was added. The resulting mixture was stirred for 1 h at 0 °C, and cold water was added. After the usual workup (toluene), anhydrous toluene (2 mL) was added and the mixture was heated to reflux for 1 h and then allowed to cool to rt. Toluene was removed under reduced pressure. Crude isocyanate was dissolved in THF (25 mL), and LiAlH₄ (745 mg, 2.03 mmol) was added. The mixture was heated to reflux for 16 h and then allowed to cool to rt. Water (400 μL) was added (*exotherm!*). After 5 min, an aqueous solution of NaOH (15%, 400 μL) was added. After 5 min, another portion of water (1.16 mL) was added. The mixture was stirred for 30 min, and MgSO₄ was added. After an additional 10 min of stirring, the mixture was filtered and concentrated under reduced pressure. Crude *N*-methylamine was dissolved in THF (14 mL), and *N*-formylbenzotriazole (390 mg, 2.65 mmol) was added. The mixture was stirred at rt for 15 h, and aqueous NaOH (2 N) was added. Stirring was continued for 10 min; then water was added. The usual workup (DCM) and purification (30 to 50% EtOAc in hexanes) afforded an inseparable mixture of *E/Z* isomers (4.0:1.0) and rotamers of **20** (555 mg, 71%) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.06 (s), 7.98 (s), and 7.92 (s) (1H), 7.52–7.50 (m, 2H), 7.36–7.34 (m, 3H), 5.83–5.69 (m, 1H), 5.17 (t, *J* = 8.5 Hz) and 4.98–4.89 (m) (3H), 3.23–3.20 (m), 3.10–2.90 (m) and 2.60–2.55 (m) (2H), 2.86 (s), 2.83 (s), 2.80 (s), and 2.77 (s) (3H), 2.31–1.85 (m), 1.82–1.40 (m), and 1.33–1.14 (m) (14H), 0.28 (s, 6H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 162.9, 139.2, 138.7, 138.0, 133.6, 124.0, 127.7, 123.0, 122.2, 122.0, 114.7, 114.3, 54.2, 52.8, 48.0, 47.4, 41.3, 41.0, 39.0, 34.6, 32.3, 32.1, 29.6, 28.7, 28.1, 27.7, 27.2, 27.0, 26.8, 26.3, 26.0, 25.1, 17.7, 17.4, –3.0; IR (film) ν (cm⁻¹) 3073, 2924, 2859, 1681, 834; MS *m/z* (rel %) 383 (9) [M⁺], 342 (63) [M⁺ – C₃H₅], 328 (13), 234 (16), 135 (100); HRMS calcd for C₂₄H₃₇N₁O₁Si: 383.2644, found: 383.2634.

rel-(15,25)-N-(2-(But-3-en-1-yl)-3-(2-(dimethylphenylsilyl)ethylidene)cycloheptylmethyl)-(trifluoromethanesulfonylmethylene)methanaminium Trifluoromethanesulfonate (32). Tf₂O (10 μL, 0.061 mmol) was added to **20** (20 mg, 0.056 mmol) and *i*-Pr₂NEt (11 μL, 0.061 mmol) in CDCl₃ (1.5 mL) at 0 °C in a NMR tube. The ¹H NMR spectrum of **32** was recorded after 15 min at rt (see the SI).

N-Methyl-5-(dimethylphenylsilylmethyl-11-(but-3-enyl)-3-azabicyclo[4.4.1]undec-6-ene (35). Tf₂O (14 μL, 0.0831 mmol) was added to **20** (30 mg, 0.078 mmol) and DTBMP (32 mg, 0.16 mmol) in DCE (1.5 mL) at 0 °C. The mixture was stirred for 5 min at rt, heated to reflux for 1 h, and then allowed to cool to rt. NaHB(OAc)₃ (83 mg, 0.39 mmol) was added, the mixture was stirred vigorously for 17 h at rt, and then saturated aqueous NaHCO₃ was added. The usual workup (EtOAc) and purification (50 to 100% EtOAc in hexanes) afforded an inseparable mixture of diastereomers of **35** (14 mg, 50%) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.51–7.48 (m, 2H), 7.34–7.32 (m, 3H), 5.77 (ddt, *J* = 17.0, 10.5, 6.5 Hz, 1H), 5.63 (t, *J* = 7.0 Hz, 1H), 4.94 (d, *J* = 17.0 Hz, 1H), 4.91 (d, *J* = 6.5 Hz, 1H), 2.89 (t, *J* = 7.5 Hz, 1H), 2.77 (dd, *J* = 11.0, 5.5 Hz, 1H), 2.64–2.57 (m, 1H), 2.42–2.23 (m, 3H), 2.14 (s) and 2.06 (s) (3H), 2.01–1.81 (m, 2H), 1.79–1.17 (m, 8H), 0.99–0.88 (m, 2H), 0.76 (d, *J* = 7.0 Hz) and 0.71 (t, *J* = 7.0 Hz) (2H), 0.27 (s) and 0.25 (s) (6H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 146.9, 139.3,

133.5, 128.7, 127.7, 122.7, 114.1, 73.9, 61.2, 49.5, 43.8, 34.6, 34.5, 33.6, 32.5, 26.1, 20.7, 17.1, -1.6, -2.0. IR (film) ν (cm⁻¹) 2926, 2921; MS m/z (rel %) 367 (28) [M⁺], 326 (11), 313 (47), 232 (51), 135 (100). HRMS calcd for C₂₄H₃₇N₃Si: 367.2695, found: 367.2703.

tert-Butyl 2-(2-(But-3-en-1-yl)-3-(methoxymethylene)cycloheptyl)acetate (36). A solution of KHMDS (0.5 M in toluene, 42.8 mL, 21.4 mmol) was added to a solution of Ph₃PCH₂OMeCl (7.33 g, 21.4 mmol) in THF (120 mL) at 0 °C. The mixture was stirred for 30 min at rt. A solution of **28/29** (2.91 g, 10.4 mmol) in THF (30 mL) was added at 0 °C, and the resulting mixture was stirred at rt for 23 h. Saturated aqueous NaHCO₃ was added, THF was removed under reduced pressure, and water was added. The usual workup (EtOAc) and purification (30 to 100% toluene in hexanes) gave a hardly separable mixture of *E/Z* and *syn/anti* isomers of **36** (3.02 g, 94%) as a colorless oil. A small portion of the mixture of diastereomers was separated for characterization. Two portions containing two different diastereomers were characterized: Portion 1 as a 3:2 mixture of diastereomers: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 5.89 (s) and 5.62 (s) (1H), 5.88–5.70 (m, 1H), 5.01–4.89 (m, 2H), 3.56 (s) and 3.49 (s) (3H), 2.56–2.48 (m), 2.40 (dd, *J* = 15.5, 4.0 Hz), and 2.34 (dd, *J* = 15.0, 4.0 Hz) (2H), 2.10–1.65 (m, 7H), 1.60–1.25 (m, 7 H), 1.44 (s, 9H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 172.9, 144.6, 143.6, 139.5, 139.0, 120.6, 119.9, 114.3, 113.9, 80.0, 79.9, 59.3, 59.0, 46.8, 41.7, 41.0, 40.6, 32.7, 32.3, 32.2, 31.9, 31.6, 29.6, 28.8, 28.1, 27.7, 23.9; IR (film) ν (cm⁻¹) 2977, 2928, 2854, 1729, 1663, 1458, 1369, 1142, 1126; MS m/z (rel %): 308 (1) [M⁺], 251 (26) [M⁺ - C₄H₉], 194 (90), 159 (86), 134 (100); HRMS (EI) calcd for C₁₅H₂₃O₃ [M⁺ - C₄H₉]: 251.1647, found 251.1657. Portion 2 as a 8:1 mixture of diastereomers, only the major diastereomer reported: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 5.85–5.72 (m) and 5.76 (s) (2H), 4.98 (d, *J* = 17.0 Hz, 1H), 4.93 (d, *J* = 10.5 Hz, 1H), 3.55 (s, 3H), 2.54–2.44 (m, 1H), 2.22–1.98 (m, 6H), 1.96–1.80 (m, 1H), 1.72–1.23 (m, 8H), 1.44 (s, 9H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 173.4, 143.9, 139.4, 119.8, 114.6, 79.9, 59.1, 45.0, 42.0, 40.3, 31.9, 31.6, 27.8, 26.1, 26.0, 25.7, 24.6; IR (film) ν (cm⁻¹) 2977, 2928, 2854, 1729, 1663, 1458, 1369, 1142, 1126; MS m/z (rel %): 251 (20) [M⁺ - C₄H₉], 220 (22), 194 (73), 159 (71), 134 (100), 57 (95), 41 (76); HRMS (EI) calcd for C₁₅H₂₃O₃ [M⁺ - C₄H₉]: 251.1647, found 251.1655.

2-(2-(But-3-en-1-yl)-3-(methoxymethylene)cycloheptyl)acetic Acid (37). KOH (2.11 g, 37.6 mmol) was added to a solution of **36** (1.16 g, 3.76 mmol) in a mixture of EtOH (145 mL) and water (3 mL). The resulting mixture was refluxed for 5 days. Then, a buffer solution (pH 7.4, 20 mL) was added and EtOH was removed under reduced pressure. Aqueous citric acid (10%) was added at 0 °C until an acidic pH (3) was obtained. The usual workup (EtOAc, washed with brine) afforded **37** (949 mg, 100%) as brown oil. For characterization, a small portion was purified by flash chromatography using silica gel (0 to 2% MeOH in DCM). An inseparable mixture of *E/Z* and *syn/anti* isomers of **37** was obtained as a brown oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 5.91 (s), 5.89–5.73 (m), 5.78 (s), and 5.64 (s) (2H), 4.99 (d, *J* = 17.5 Hz, 1H), 4.94 (d, *J* = 10.5 Hz, 1H), 3.57 (s), 3.56 (s), and 3.50 (s) (3H), 2.79 (dt, *J* = 11.5, 3.5 Hz) and 2.60–2.40 (m) (1H), 2.40–1.22 (m, 15H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 180.8, 145.0, 144.0, 139.6, 139.4, 139.1, 120.2, 119.7, 119.5, 114.7, 114.4, 114.2, 59.1, 58.8, 46.6, 45.0, 41.3, 41.0, 40.6, 40.2, 40.0, 39.7, 39.6, 38.7, 32.2, 32.0, 31.7, 31.6, 31.2, 29.1, 28.8, 28.4, 27.8, 27.3, 26.1, 25.8, 25.7, 25.2, 24.9, 24.6, 23.4; IR (film) ν (cm⁻¹) 3081, 2927, 2856, 1706, 1452, 1408, 1217, 1125; MS m/z (rel %): 252 (4) [M⁺], 220 (9), 197 (53), 134 (100), 119 (46); HRMS (EI) calcd for C₁₅H₂₄O₃ [M⁺]: 252.1725, found 252.1727.

N-((2-(But-3-en-1-yl)-3-(methoxymethylene)cycloheptyl)methyl)-N-methylformamide (38). Following the procedure used to prepare **20**, a solution of **37** (1.01 g, 3.98 mmol) in acetone (14.0 mL) was treated with ClCO₂Et (395 μ L, 4.18 mmol) and *i*-Pr₂NEt (0.87 mL, 5.0 mmol) for 30 min at 0 °C and then with an aqueous solution of NaN₃ (5.9 M, 1.35 mL, 7.96 mmol) for 1 h at 0 °C. Crude acylazide was then refluxed in toluene (14.0 mL) for 1.5 h to afford the corresponding isocyanate (993 mg) as a brown oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 5.91 (s), 5.82 (s), 5.78 (s), and 5.67 (s) (1H),

5.87–5.72 (m, 1H), 5.03–4.92 (m, 2H), 3.57 (s), 3.56 (s), 3.52 (s), and 3.50 (s) (3H), 3.41–3.09 (m) and 3.18 (dd, *J* = 7.5, 3.5 Hz) (2H), 2.97 (d, *J* = 12.0 Hz) and 2.65–2.49 (m) (1H), 2.22–1.19 (m, 13H). A solution of crude isocyanate (993 mg, 3.98 mmol) in THF (25 mL) was treated with LiAlH₄ (755 mg, 19.9 mmol) at reflux for 20 h and then with water (750 μ L), aqueous NaOH (15%, 750 μ L), and water (2.25 mL) to afford *N*-methylamine (845 mg, 89%) as pale yellow oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 5.91–5.70 (m), 5.80 (s), and 5.63 (s) (2H), 4.99 (d, *J* = 19.0 Hz, 1H), 4.94 (d, *J* = 10.5 Hz, 1H), 3.56 (s), 3.54 (s), 3.50 (s), and 3.49 (s) (3H), 2.62–2.46 (m), 2.44–2.31 (m), 2.42 (s), and 2.41 (s) (4H), 2.21–1.78 (4H), 1.72–1.18 (m, 11H), 0.98–0.75 (m, 1H); IR (film) ν (cm⁻¹) 3358, 3325, 3073, 2925, 2852, 2788, 1661, 1639, 1461, 1444, 1247, 1220, 1125, 907. A solution of crude *N*-methylamine (845 mg, 3.56 mmol) in THF (24 mL) was treated with *N*-formylbenzotriazole (680 mg, 4.63 mmol) for 18 h at rt and then with aqueous NaOH (2 N). The usual workup (DCM) and purification (10 to 40% EtOAc in hexanes) afforded an inseparable mixture of diastereomers and rotamers of **38** (820 mg, 78% over 4 steps) as a pale yellow oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.09 (s), 8.07 (s), 8.01 (s), 7.99 (s), and 7.98 (s) (1H), 5.92–5.64 (m) and 5.77 (s) (2H), 5.06–4.89 (m, 2H), 3.57 (s), 3.56 (s), 3.55 (s), 3.54 (s), and 3.50 (s) (3H), 3.30 (dd, *J* = 13.5, 7.5 Hz), 3.20 (dd, *J* = 13.5, 8.0 Hz), 3.14 (dd, *J* = 14.0, 8.0 Hz), and 3.02 (dd, *J* = 14.0, 7.5 Hz) (2H), 2.92 (s), 2.92 (s), 2.90 (s), 2.87 (s), and 2.83 (s) (3H), 2.62–2.47 (m) and 2.24–1.07 (m) (14H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 163.7, 163.5, 163.2, 145.2, 144.2, 143.8, 143.5, 139.4, 139.3, 139.0, 138.8, 119.9, 119.4, 119.3, 119.0, 115.0, 114.6, 114.5, 114.2, 59.1, 58.9, 54.2, 53.3, 53.0, 48.4, 47.5, 47.1, 45.7, 44.9, 44.5, 43.9, 43.4, 42.9, 42.1, 41.8, 41.0, 40.2, 40.0, 37.9, 36.0, 34.4, 33.8, 32.7, 32.4, 32.2, 31.9, 31.7, 31.5, 31.3, 31.1, 29.6, 29.3, 29.2, 29.1, 28.7, 28.3, 28.2, 27.5, 27.2, 26.9, 26.8, 26.5, 26.3, 25.6, 25.4, 25.1, 24.9, 24.6, 24.5, 24.4, 24.2, 24.0, 23.5; IR (film) ν (cm⁻¹) 3073, 2924, 2850, 1666, 1453, 1395, 1222, 1123; MS m/z (rel %): 264 (1) [M⁺], 250 (4), 206 (9), 174 (15), 151 (100); HRMS (EI) calcd for C₁₆H₂₆NO₂ [M⁺ - H]: 264.1963, found 264.1967.

N-((2-(But-3-en-1-yl)-3-formylcycloheptyl)methyl)-N-methylformamide (39). An aqueous HCl solution (2 N, 5.20 mL, 10.4 mmol) was added to a solution of **38** (527 mg, 1.99 mmol) in THF (10 mL). The reaction mixture was heated at 55 °C for 3 h; then saturated aqueous NaHCO₃ was added. The usual workup (Et₂O) and purification (40 to 70% EtOAc in hexanes) afforded a mixture of diastereomers and rotamers of **39** (410 mg, 82%) as a pale yellow oil. Only the major fraction containing two diastereomers was characterized: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 9.63 (s) and 9.62 (s) (1H), 8.09 (s) and 8.00 (s) (1H), 5.87–5.70 (m, 1H), 5.09–4.90 (m, 2H), 3.47 (dd, *J* = 13.5, 8.5 Hz) and 3.22–3.00 (m) (2H), 2.92 (s) and 2.85 (s) (3H), 2.54–2.46 (m, 1H), 2.24–1.27 (m, 14H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 205.6, 204.9, 163.5, 163.4, 138.7, 138.0, 115.8, 115.1, 53.7, 53.3, 47.4, 35.6, 35.3, 35.0, 34.3, 31.8, 31.6, 29.4, 27.1, 27.0, 26.8, 26.4, 25.9, 25.6, 25.4, 24.4; IR (film) ν (cm⁻¹) 2928, 2861, 1721, 1674, 1452, 1395, 1076; MS m/z (rel %): 252 (14) [MH⁺], 251 (8) [M⁺], 222 (30) [M⁺ - CHO], 192 (58), 172 (55), 95 (82), 81 (100); HRMS (EI) calcd for C₁₅H₂₅NO₂ [M⁺]: 251.1885, found 251.1896.

N-((2-(But-3-en-1-yl)-3-((tert-butyl)dimethylsilyloxy)methyl)cycloheptyl)methyl)-N-methylformamide (40). TBDMSOTf (201 μ L, 0.877 mmol) was added to a solution of **39** (147 mg, 0.585 mmol) and *i*-Pr₂NEt (153 μ L, 0.877 mmol) in DCM (10 mL) at 0 °C. The solution was stirred for 18 h at rt; then saturated aqueous Na₂CO₃ and saturated aqueous NaCl were added. The usual workup (DCM) and purification using silica gel saturated with Et₃N (25% EtOAc in hexanes) afforded a mixture of diastereomers and rotamers of **40** (160 mg, 75%) as a pale yellow oil, separable in two different portions for characterization: Portion 1: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.09 (s), 8.05 (s), 8.00 (s), and 7.98 (s) (1H), 6.20 (s), 6.07 (s), and 6.04 (s) (1H), 5.88–5.72 (m, 1H), 5.05–4.84 (m, 2H), 3.42 (dd, *J* = 13.5, 8.5 Hz), 3.18 (dd, *J* = 14.0, 7.0 Hz), 3.14 (dd, *J* = 13.5, 7.0 Hz), and 3.06 (dd, *J* = 14.0, 8.0 Hz) (2H), 2.91 (s) and 2.85 (s) (3H), 2.24–2.10 (m) and 2.08–1.04 (m) (14H), 0.91 (s, 9H), 0.11 (s, 6H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 163.7,

163.2, 139.7, 139.2, 135.9, 135.5, 122.7, 121.6, 114.7, 114.3, 54.6, 53.8, 47.6, 41.3, 40.1, 39.9, 38.0, 36.5, 36.0, 34.3, 33.1, 32.3, 32.1, 31.7, 31.4, 29.4, 29.3, 28.7, 28.4, 27.8, 27.4, 27.1, 26.9, 25.3, 24.9, 24.7, 24.3, 17.8, -5.8, -5.9; IR (film) ν (cm⁻¹) 2953, 2928, 2857, 1682, 1462, 1387, 1254, 1164; MS (EI) m/z (rel %): 365 [M⁺] (1), 350 [M⁺ - CH₃] (3), 308 [M⁺ - C₄H₉] (100), 251 (66); HRMS (EI) calcd for C₂₁H₃₈NO₂Si [M⁺ - H] 364.2672, found 364.2680. Portion 2: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.09 (s), 8.07 (s), 7.99 (s), and 7.97 (s) (1H), 6.07 (s) and 5.92 (s) (1H), 5.84–5.69 (m, 1H), 5.04–4.90 (m, 2H), 3.32 (dd, J = 13.5, 7.5 Hz), 3.22–3.08 (m), 3.15 (dd, J = 14.0, 8.0 Hz), and 3.01 (dd, J = 14.0, 7.5 Hz) (2H), 2.91 (s), 2.88 (s), 2.84 (s), and 2.82 (s) (3H), 2.70–2.55 (m), 2.13–1.90 (m), and 1.87–1.17 (m) (14H), 0.91 (s, 9H), 0.11 (s, 6H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 163.6, 163.3, 139.5, 139.0, 136.2, 135.8, 123.7, 123.1, 115.0, 114.5, 54.3, 53.3, 47.6, 44.4, 42.9, 42.1, 41.9, 34.3, 32.6, 32.4, 31.9, 31.7, 31.5, 29.9, 29.4, 29.3, 29.2, 28.3, 27.9, 26.7, 26.5, 25.7, 25.5, 25.3, 24.7, 24.6, 23.5, 17.9, -5.9; IR (film) ν (cm⁻¹) 3074, 2927, 2856, 1681, 1392, 1253, 1163; MS (EI) m/z (rel %): 365 [M⁺] (1), 35 [M⁺ - CH₃] (2), 308 [M⁺ - C₄H₉] (100), 251 (56); HRMS (EI) calcd for C₂₁H₃₈NO₂Si [M⁺ - H] 364.2672, found 364.2666.

rel-(1S,6S)-10-(But-3-en-1-yl)-8-methyl-8-azabicyclo[4.3.1]-decane-1-carbaldehyde (43). Tf₂O (41 μ L, 0.24 mmol) was added to a solution of 40 (81 mg, 0.22 mmol) and DTBMP (50 mg, 0.24 mmol) in DCE (3.0 mL) at rt. After 15 min, the solution was heated at 80 °C for 3 h. Progression of the reaction was monitored by ¹H NMR. The mixture was concentrated under reduced pressure, and the product was solubilized in MeOH (3.0 mL). NaBH₄ (42 mg, 1.1 mmol) was added at 0 °C, and the mixture was stirred at rt for 6 h. Aqueous NaOH (1 N) was added, and solvent was removed under reduced pressure. Water was added. The usual workup (DCM) and purification (0 to 5% EtOAc in hexanes) afforded a hardly separable mixture of diastereomers of 43 (25 mg, 48%) as a yellow oil. A small portion of the major diastereomer was isolated and characterized: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 9.32 (s, 1H), 5.74 (ddt, J = 17.0, 10.0, 7.0 Hz, 1H), 5.00 (d, J = 17.0 Hz) and 4.97 (d, J = 10.0 Hz) (2H), 2.41 (d, J = 12.5 Hz) and 2.38 (d, J = 12.5 Hz) (2H), 2.24–2.10 (m) and 2.21 (s) (6H), 2.02–1.85 (m, 5H), 1.80–1.70 (m, 2H), 1.67–1.46 (m, 5H), 1.15–1.07 (m, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 203.2, 138.0, 115.2, 57.6, 57.5, 52.0, 47.1, 36.3, 35.7, 35.5, 34.5, 32.8, 29.3, 26.7, 26.6; IR (film) ν (cm⁻¹) 2933, 2846, 2792, 2692, 1723, 1465, 1446; MS (EI) m/z (rel %): 235 [M⁺] (32), 206 (100); HRMS (EI) calcd for C₁₅H₂₅NO [M⁺] 235.1936, found 235.1935.

(9H-Fluoren-9-yl)methyl N-((2-(But-3-en-1-yl)-3-(methoxymethylene)cycloheptyl)methyl)carbamate (44). Following the procedure used to prepare 20, a solution of 37 (819 mg, 3.24 mmol) in acetone (11 mL) was treated with ClCO₂Et (321 μ L, 3.41 mmol) and *i*-Pr₂N₂Et (0.70 mL, 4.1 mmol) for 30 min at 0 °C and then with an aqueous solution of NaN₃ (5.9 M, 1.10 mL, 6.50 mmol) for 1 h at 0 °C. Crude acylazide was then refluxed in toluene (11.0 mL) for 1.5 h to afford the corresponding isocyanate. The latter was dissolved in benzene (24 mL); then 9-fluorene-methanol (954 mg, 4.86 mmol) and Ti(*O**t*-Bu)₄ (248 μ L, 0.648 mmol) were added at 0 °C. The mixture was refluxed for 3 h; then saturated aqueous NH₄Cl was added. The usual workup (Et₂O) and purification (5 to 25% EtOAc in hexanes) afforded an inseparable mixture of diastereomers of 44 (1.32 g, 92%) as a pale yellow oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.77 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 5.90–5.72 (m) and 5.63 (s) (2H), 5.05–4.89 (m, 2H), 4.78–4.70 (m, 1H), 4.46–4.35 (m, 2H), 4.23 (t, J = 7.0 Hz, 1H), 3.56 (s), 3.54 (s), 3.50 (s), and 3.48 (s) (3H), 3.20–2.82 (m, 2H), 2.59–2.46 (m) and 2.18–1.78 (m) (4H), 1.77–1.13 (m, 10H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 157.0 (s), 156.7 (s), 144.5 (s), 144.2 (s), 143.8 (s), 143.6 (d), 143.3 (d), 141.5 (s), 139.3 (d), 139.2 (d), 127.7 (d), 127.1 (d), 125.1 (d), 120.0 (d), 119.6 (s), 114.6 (t), 114.4 (t), 114.3 (t), 66.5 (t), 66.1 (t), 59.0 (q), 58.9 (q), 46.9 (d), 45.2 (d), 45.0 (d), 44.5 (t), 44.4 (t), 43.3 (d), 43.2 (d), 43.0 (d), 37.6 (d), 37.4 (d), 32.4 (t), 32.1 (t), 31.9 (t), 31.6 (t), 31.4 (t), 31.0 (t), 30.0 (t), 29.6 (t), 29.4 (t), 29.2 (t), 28.5 (t), 28.3 (t), 27.4 (t), 26.7 (t), 26.1 (t), 25.6 (t), 25.4 (t), 25.0 (t), 24.9 (t), 24.3 (t), 23.5 (t); IR (film) ν

(cm⁻¹) 3420, 3340, 3067, 3008, 2927, 2859, 1722, 1694, 1537, 1519, 1449, 1249, 1124; MS (EI) m/z (rel %): 445 [M⁺] (1), 178 (100), 151 (20), 148 (18); HRMS (EI) calcd for C₂₉H₃₅NO₃ [M⁺] 445.2617, found 445.2626.

N-((2-(But-3-en-1-yl)-3-(methoxymethylene)cycloheptyl)methyl)-N-((trimethylsilyl)methyl)formamide (45). NaH (60% in mineral oil, 143 mg, 3.58 mmol) was added to a solution of 44 (1.06 g, 2.38 mmol) in THF (28 mL) and DMF (14 mL) at rt. The reaction mixture was stirred at 75 °C for 1 h; then TMSI (530 μ L, 3.57 mmol) was added. The solution was stirred at 75 °C for 3.5 h, and aqueous NaOH (1 N) was added. The usual workup (Et₂O) afforded the corresponding secondary amine as a yellow oil. The latter was solubilized in THF (20 mL); then *N*-formylbenzotriazole (454 mg, 3.09 mmol) was added. The resulting solution was stirred at rt for 15 h. Aqueous NaOH (1 N) was added, and solvent was removed under reduced pressure. The usual workup (DCM) and purification (0 to 5% Et₂O in DCM) afforded a hardly separable mixture of diastereomers and rotamers of 45 (485 mg, 60% over 2 steps) as a pale yellow oil. Only one fraction containing two diastereomers was characterized: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.06 (s), 8.05 (s), 7.97 (s), and 7.96 (s) (1H), 5.85–5.70 (m) and 5.77 (s) (2H), 5.03–4.89 (m, 2H), 3.56 (s), 3.55 (s), and 3.50 (s) (3H), 3.28–2.93 (m, 2H), 2.88–2.70 (m), 2.85 (d, J = 14.0 Hz), and 2.75 (d, J = 15.0 Hz) (2H), 2.61–2.50 (m) and 2.22–1.09 (m) (14H), 0.11 (s) and 0.09 (s) (9H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 163.0, 162.4, 143.9, 143.6, 139.6, 139.4, 139.2, 139.0, 120.2, 119.6, 115.0, 114.7, 114.4, 59.2, 58.9, 53.3, 52.9, 47.6, 47.2, 43.1, 42.4, 41.8, 41.5, 39.9, 37.9, 37.4, 36.8, 36.5, 33.2, 33.0, 32.2, 32.0, 31.9, 31.7, 29.3, 29.1, 28.5, 28.3, 27.0, 26.6, 26.5, 25.7, 25.5, 25.2, 24.8, 24.6, 24.3, -1.9, -2.4; IR (film) ν (cm⁻¹) 2931, 2869, 1664, 1646, 1452, 1249, 853; MS (EI) m/z (rel %): 337 [M⁺] (1), 322 [M⁺ - CH₃] (100), 306 (23), 151 (66); HRMS (EI) calcd for C₁₈H₃₂NO₂Si [M⁺ - CH₃] 322.2202, found: 322.2207.

N-((2-(But-3-en-1-yl)-3-formylcycloheptyl)methyl)-N-((trimethylsilyl)methyl)formamide (46). Trichloroacetic acid (1.38 g, 8.45 mmol) was added to a solution of 45 (569 mg, 1.69 mmol) in DCM (45 mL). Water (3–4 drops) was added, and the resulting solution was stirred for 15 h at rt. Saturated aqueous NaHCO₃ and saturated aqueous NaCl were added. The usual workup (DCM) and purification (30% EtOAc in hexanes) afforded a mixture of diastereomers and rotamers of 46 (448 mg, 82%) as a colorless oil, separable in two different portions for characterization: Portion 1: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 9.72 (s), 9.63 (s), and 9.62 (s) (1H), 8.07 (s), 8.00 (s), and 7.98 (s) (1H), 5.85–5.71 (m, 1H), 5.08–4.91 (m, 2H), 3.43 (dd, J = 13.5, 8.0 Hz), 3.14 (dd, J = 14.0, 7.0 Hz), and 3.05 (dd, J = 14.0, 7.5 Hz) (2H), 2.86 (s), 2.79 (d, J = 9.0 Hz), and 2.72 (d, J = 7.5 Hz) (2H), 2.52–2.46 (m, 1H), 2.18–1.20 (m, 14H), 0.11 (s) and 0.09 (s) (9H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 205.6, 205.0, 163.3, 162.4, 138.7, 138.1, 115.8, 115.2, 53.4, 53.2, 47.4, 37.7, 35.8, 34.9, 33.4, 31.8, 31.6, 28.6, 27.3, 27.1, 26.8, 26.5, 26.1, 25.5, 24.6, 24.3, -1.9, -2.4; IR (film) ν (cm⁻¹) 2929, 2856, 1721, 1667, 1452, 1390, 1249; MS (EI) m/z (rel %): 323 [M⁺] (2), 308 [M⁺ - CH₃] (92), 294 [M⁺ - CHO] (44), 282 (55), 145 (100); HRMS (IE) calcd for C₁₈H₃₃NO₂Si [M⁺] 323.2280, found: 323.2290. Portion 2: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 9.77 (s), 9.72 (s), and 9.62 (s) (1H), 8.08 (s), 8.06 (s), 8.00 (s), and 7.98 (s) (1H), 5.82–5.63 (m, 1H), 5.06–4.93 (m, 2H), 3.39–2.96 (m), 3.32 (t, J = 8.0 Hz), 3.20 (dd, J = 14.0, 6.5 Hz), and 3.10 (dd, J = 14.0, 8.0 Hz) (2H), 2.85 (d, J = 15.0 Hz), 2.79 (d, J = 15.5 Hz), 2.75 (s), and 2.55–2.47 (m) (2H), 2.38–2.20 (m) and 2.17–0.85 (m) (15H), 0.13 (s), 0.11 (s), and 0.10 (s) (9H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 205.8, 205.6, 205.1, 163.1, 162.6, 162.4, 138.6, 138.1, 138.0, 115.7, 115.3, 57.1, 54.5, 54.1, 53.9, 49.0, 42.7, 42.4, 41.3, 38.6, 38.0, 37.7, 37.1, 34.2, 33.8, 32.9, 28.7, 28.5, 28.0, 27.7, 26.9, 25.2, 25.0, 24.6, 23.0, -1.8, -2.4; IR (film) ν (cm⁻¹) 3075, 2931, 2861, 1721, 1666, 1443, 1390, 1249; MS (EI) m/z (rel %): 323 [M⁺] (2), 308 [M⁺ - CH₃] (33), 294 [M⁺ - CHO] (23), 145 (100); HRMS (EI) calcd for C₁₈H₃₃NO₂Si [M⁺] 323.2280, found: 323.2287.

N-((2-(But-3-en-1-yl)-3-((tert-butyl)dimethylsilyloxy)methylene)cycloheptyl)methyl)-N-((trimethylsilyl)methyl)formamide (47). Following the procedure used to prepare 40, a solution of 46

(228 mg, 0.705 mmol) in DCM (12 mL) was treated with TBDMSOTf (260 μ L, 1.13 mmol) and *i*-Pr₂NEt (197 μ L, 1.13 mmol) for 20 h at rt to afford, after the usual purification using silica gel saturated with Et₃N (10% EtOAc in hexanes), an inseparable mixture of diastereomers and rotamers of **47** (184 mg, 60%) as a pale yellow oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.08 (s), 8.05 (s), 8.03 (s), 7.97 (s), 7.97 (s), and 7.95 (s) (1H), 6.07 (s) and 5.92 (s) (1H), 5.85–5.70 (m, 1H), 5.03–4.89 (m, 2H), 3.32 (dd, *J* = 13.5, 7.5 Hz), 3.21 (dd, *J* = 13.5, 8.0 Hz), 3.17–2.57 (m), 3.12 (dd, *J* = 14.0, 7.5 Hz), 3.00 (dd, *J* = 14.0, 7.5 Hz), 2.86 (d, *J* = 15.0 Hz), 2.73 (d, *J* = 15.0 Hz), and 2.51 (d, *J* = 15.0 Hz) (4H), 2.17–1.06 (m, 14H), 0.92 (s) and 0.91 (s) (9H), 0.12 (s), 0.10 (s), 0.09 (s), and 0.08 (s) (15 H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 163.1, 162.6, 162.4, 162.2, 139.7, 139.6, 139.3, 139.1, 136.4, 136.2, 136.0, 135.8, 123.9, 123.3, 122.0, 121.5, 115.0, 114.7, 114.6, 114.3, 54.2, 53.6, 53.0, 47.6, 45.0, 44.6, 43.0, 42.3, 41.8, 41.7, 41.5, 39.6, 37.7, 37.0, 33.8, 33.3, 33.1, 32.4, 32.2, 31.9, 31.7, 31.5, 29.3, 28.5, 28.4, 27.9, 27.2, 26.9, 26.6, 25.8, 25.5, 25.4, 24.8, 24.7, 23.6, 17.9, –1.8, –1.9, –2.4, –5.8; MS (EI) *m/z* (rel %): 437 [M⁺] (2), 422 [M – CH₃]⁺ (23), 380 [M⁺ – C₄H₉] (100), 251 (49); HRMS (EI) calcd for C₂₄H₄₇NO₂Si₂ [M⁺] 437.3145, found 437.3138.

rel-(1S,6S)-10-(But-3-en-1-yl)-1-formyl-8-((trimethylsilyl)methyl)-8-aza-bicyclo[4.3.1]dec-8-en-8-ium Trifluoromethanesulfonate (49). Tf₂O (12 μ L, 73 μ mol) was added to a solution of **47** (29 mg, 66 μ mol) and DTBMP (15 mg, 73 μ mol) in DCE (0.75 mL) at rt. After 15 min, additional DCE (7.5 mL) and DMAD (24 μ L, 0.20 mmol) were added. Then, the solution was heated at 55 °C for 3 h. ¹H NMR analysis of an aliquot showed the formation of the iminium ion **49**: ¹H NMR (300 MHz, CDCl₃) characteristic signals δ (ppm) 9.70 (s) and 9.63 (s) (1H), 8.46 (s, 1H), 5.83–5.69 (m, 1H), 5.02 (d, *J* = 10.0 Hz, 1H), 5.01 (d, *J* = 18.0 Hz, 1H), 3.94–3.77 (m, 1H), 3.45–3.31 (m, 1H), 3.14–3.08 (m) and 2.60–2.53 (m) (2H), 2.17–1.18 (m, 14H), 0.16 (s, 9H).

2-(((2-(But-3-en-1-yl)-3-(methoxymethylene)cycloheptyl)methyl)amino)acetonitrile (56). NaH (60% in mineral oil, 237 mg, 5.92 mmol) was added to a solution of **44** (1.32 g, 2.96 mmol) in THF (34 mL) and DMF (17 mL) at rt. The mixture was stirred at 75 °C for 1 h; then BrCH₂CN (395 μ L, 5.92 mmol) was added. The resulting solution was stirred at 75 °C for 2 h, and saturated aqueous NaHCO₃ was added. The usual workup (EtOAc) and purification using silica gel saturated with Et₃N (10 to 40% EtOAc in hexanes) afforded an inseparable mixture of diastereomers of **56** (683 mg, 88%) as an orange oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 5.91 (s), 5.88–5.73 (m), 5.80 (s), 5.75 (s), and 5.64 (s) (2H), 5.00 (d, *J* = 17.5 Hz, 1H), 4.95 (d, *J* = 10.5 Hz, 1H), 3.61 (s), 3.58 (s), 3.56 (s), 3.55 (s), and 3.51 (s) (5H), 2.66 (dd, *J* = 11.5, 6.5 Hz) and 2.58–2.49 (m) (3H), 2.18–2.00 (m, 3H), 1.92–1.79 (m, 1H), 1.73–1.06 (m, 10H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 144.2, 143.2, 142.9, 142.8, 138.8, 138.8, 138.6, 138.5, 119.7, 119.3, 119.3, 119.2, 117.7, 117.7, 114.0, 113.8, 113.7, 58.9, 58.8, 58.7, 58.6, 53.4, 53.4, 52.4, 52.3, 44.9, 44.8, 44.4, 43.5, 43.0, 42.6, 38.1, 37.2, 37.1, 37.0, 36.7, 36.7, 32.5, 32.2, 32.0, 31.7, 31.6, 31.5, 31.3, 30.5, 29.9, 29.8, 29.7, 29.1, 28.6, 28.2, 28.0, 27.3, 27.0, 26.4, 25.6, 25.5, 25.3, 24.5, 24.2, 23.5; IR (film) ν (cm⁻¹) 2927, 2854, 1663, 1459, 1222, 1124; MS (Cl:NH₃) *m/z* (rel %): 262 [M⁺] (8), 220 (27), 161 (35), 148 (100); HRMS (Cl:NH₃) calcd for C₁₆H₂₆N₂O [M⁺] 262.2045, found: 262.2045.

N-((2-(But-3-en-1-yl)-3-(methoxymethylene)cycloheptyl)methyl)-N-(cyanomethyl)formamide (57). *N*-Formylbenzotriazole (288 mg, 1.96 mmol) was added to a solution of **56** (427 mg, 1.63 mmol) in THF (22 mL). The resulting mixture was stirred at rt for 18 h. Aqueous NaOH (2 N) was added, and solvent was removed under reduced pressure. The usual workup (DCM) and purification (30 to 40% EtOAc in hexanes) afforded an inseparable mixture of diastereomers and rotamers of **57** (415 mg, 88%) as a pale yellow oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.09 (s), 7.98 (s), 7.96 (s), and 7.94 (s) (1H), 5.87 (s), 5.83–5.51 (m), 5.76 (s), and 5.59 (s) (2H), 5.04–4.79 (m, 2H), 4.33–4.03 (m, 2H), 3.49 (s), 3.48 (s), 3.47 (s), and 3.44 (s) (3H), 3.34–3.02 (m, 2H), 2.53–2.38 (m, 1H), 2.14–1.08 (m, 13H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 162.8, 162.5, 162.3, 162.1, 144.9, 143.9, 143.7, 143.4, 138.6, 138.5, 138.1, 118.1,

118.0, 114.9, 114.7, 114.5, 114.4, 59.1, 58.9, 52.2, 51.1, 46.1, 44.5, 42.9, 42.2, 41.9, 41.0, 37.7, 35.8, 32.8, 32.3, 31.8, 31.6, 31.4, 31.3, 30.1, 28.9, 28.5, 28.4, 28.3, 27.2, 26.7, 26.4, 26.2, 25.9, 25.5, 24.7, 23.7; IR (film) ν (cm⁻¹) 2929, 2863, 1681, 1429, 1223, 1179, 1123; MS (EI) *m/z* (rel %): 290 [M⁺] (2), 275 [M⁺ – CH₃] (4), 206 (26), 174 (34), 148 (100); HRMS (EI) calcd for C₁₇H₂₆N₂O₂ [M⁺] 290.1994, found: 290.1995.

N-((2-(But-3-en-1-yl)-3-formylcycloheptyl)methyl)-N-(cyanomethyl)formamide (58). Trichloroacetic acid (1.16 g, 7.11 mmol) was added to a solution of **57** (413 mg, 1.42 mmol) in DCM (36 mL). Water (4–5 drops) was added, and the resulting solution was stirred for 18 h at rt. Saturated aqueous NaHCO₃ and saturated aqueous NaCl were added. The usual workup (DCM) and purification (80 to 100% Et₂O in hexanes) afforded a mixture of diastereomers and rotamers of **58** (315 mg, 80%) as a pale yellow oil separable in two different portions for characterization: Portion 1: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 9.76 (s) and 9.61 (s) (1H), 8.14 (s), 8.04 (s), and 7.99 (s) (1H), 5.79–5.63 (m, 1H), 5.02–4.89 (m, 2H), 4.69 (d, *J* = 17.5 Hz), 4.39 (d, *J* = 18.0 Hz), 4.34 (d, *J* = 17.5 Hz), 4.30 (d, *J* = 18.0 Hz), 4.15 (d, *J* = 17.5 Hz), and 4.14 (d, *J* = 17.5 Hz) (2H), 3.79 (dd, *J* = 14.0, 10.0 Hz), 3.35 (dd, *J* = 7.0, 5.5 Hz), 3.27 (dd, *J* = 14.5, 8.5 Hz), 3.20 (dd, *J* = 14.5, 7.0 Hz), and 2.98 (dd, *J* = 14.0, 6.0 Hz) (2H), 2.57–2.48 (m, 1H), 2.14–1.97 (m, 3H), 1.93–1.78 (m, 3H), 1.68–1.52 (m, 3H), 1.50–1.31 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 206.4, 205.9, 205.5, 163.3, 162.9, 162.8, 138.5, 137.8, 137.7, 116.0, 115.9, 115.2, 115.0, 53.7, 52.8, 52.7, 52.6, 51.0, 44.9, 41.7, 36.4, 35.1, 34.3, 34.1, 34.1, 33.8, 31.6, 31.3, 31.1, 29.9, 29.4, 27.9, 27.7, 26.8, 26.4, 26.3, 26.0, 25.8, 25.7, 25.5, 25.4, 24.4, 24.0, 23.9; IR (film) ν (cm⁻¹) 2930, 2863, 1719, 1680, 1432, 1399; MS (EI) *m/z* (rel %): 276 [M⁺] (9), 247 [M – CHO]⁺ (10), 233 [M⁺ – CH₂CN] (8), 192 (57), 137 (62), 95 (100); HRMS (EI) calcd for C₁₆H₂₄N₂O₂ [M⁺] 276.1838, found: 276.1836. Portion 2: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 9.68 (s) and 9.67 (s) (1H), 8.16 (s) and 8.03 (s) (1H), 5.72–5.61 (m, 1H), 4.99–4.90 (m, 2H), 4.36 (d, *J* = 17.5 Hz), 4.22 (d, *J* = 4.5 Hz), and 4.17 (d, *J* = 17.5 Hz) (2H), 3.55 (dd, *J* = 14.0, 8.0 Hz), 3.38 (dd, *J* = 14.5, 7.5 Hz), 3.30 (dd, *J* = 14.0, 8.0 Hz), and 3.23 (dd, *J* = 14.5, 8.0 Hz) (2H), 2.39–2.23 (m, 2H), 2.07–1.88 (m, 3H), 1.80–1.49 (m, 7H), 1.44–1.19 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 204.6, 204.1, 162.4, 137.9, 137.4, 115.6, 115.1, 114.9, 114.7, 56.7, 52.8, 47.7, 42.7, 37.8, 37.3, 36.3, 33.1, 33.0, 30.6, 29.0, 28.7, 25.3, 25.1, 24.8, 24.8, 24.7, 24.7, 23.2; IR (film) ν (cm⁻¹) 2931, 2864, 1719, 1679, 1433, 1402, 1181; MS (EI) *m/z* (rel %): 276 [M⁺] (8), 247 [M⁺ – CHO] (9), 233 [M⁺ – CH₂CN] (7), 192 (65), 95 (96), 81 (100); HRMS (EI) calcd for C₁₆H₂₄N₂O₂ [M⁺] 276.1838, found: 276.1839.

N-((2-(But-3-en-1-yl)-3-(((tert-butyl)dimethylsilyloxy)methyl)cycloheptyl)methyl)-N-(cyanomethyl)formamide (59). Following the procedure used to prepare **40**, a solution of **58** (145 mg, 0.525 mmol) in DCM (9 mL) was treated with TBDMSOTf (193 μ L, 0.839 mmol) and *i*-Pr₂NEt (146 μ L, 0.839 mmol) for 7 h at rt to afford, after the usual purification using silica gel saturated with Et₃N (0 to 40% EtOAc in hexanes), a mixture of diastereomers and rotamers of **59** (113 mg, 55%) as a pale yellow oil separable in two different portions for characterization: Portion 1: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.11 (s), 8.04 (s), and 8.01 (s) (1H), 6.24 (s), 6.07 (s), and 6.05 (s) (1H), 5.77 (ddt, *J* = 17.0, 10.0, 7.0 Hz, 1H), 5.01–4.88 (m, 2H), 4.58 (d, *J* = 17.5 Hz), 4.36 (d, *J* = 17.5 Hz), 4.25 (d, *J* = 17.5 Hz), 4.15 (d, *J* = 18.0 Hz), 4.14 (d, *J* = 17.5 Hz), and 4.10 (d, *J* = 17.5 Hz) (2H), 3.69 (dd, *J* = 14.0, 9.5 Hz), 3.39 (dd, *J* = 14.5, 4.5 Hz), 3.32 (dd, *J* = 14.5, 8.5 Hz), 3.23 (dd, *J* = 14.5, 7.5 Hz), and 3.19–3.14 (m) (2H), 2.80 (d, *J* = 12.0 Hz), 2.75–2.70 (m), and 2.67–2.63 (m) (1H), 2.19–2.13 (m, 1H), 2.02–1.93 (m, 2H), 1.83–1.45 (m) and 1.42–1.33 (m) (8H), 1.26–1.11 (m, 2H), 0.91 (s) and 0.90 (s) (9H), 0.12 (s) and 0.11 (s) (6H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 162.7, 162.2, 161.8, 138.9, 138.8, 138.5, 137.2, 135.9, 135.4, 121.8, 120.8, 114.9, 114.4, 114.3, 52.6, 50.8, 45.2, 41.4, 40.1, 39.9, 38.0, 35.9, 35.7, 35.4, 33.3, 32.4, 32.3, 31.6, 31.5, 30.3, 29.8, 29.7, 29.5, 28.9, 28.7, 28.6, 27.5, 27.3, 27.1, 25.7, 25.4, 25.2, 24.8, 24.4, 18.2, –5.2, –5.4; IR (film) ν (cm⁻¹) 2960, 2929, 2859, 1687, 1463, 1429, 1387, 1254, 1164, 1141; MS (EI) *m/z* (rel %): 390 [M⁺] (1), 333 [M⁺ – C₄H₉] (100), 306 (25), 251 (45); HRMS (EI) calcd for C₂₂H₃₈N₂O₂Si [M⁺]

390.2702, found: 390.2703. Portion 2: ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.14 (s), 8.01 (s), and 8.00 (s) (1H), 6.10 (s), 6.07 (s), and 5.93 (s) (1H), 5.79–5.69 (m, 1H), 4.97 (dd, $J = 17.0, 1.5$ Hz, 1H), 4.96 (d, $J = 10.0$ Hz, 1H), 4.22 (s), 4.14 (s), and 4.13 (s) (2H), 3.42 (dd, $J = 14.0, 7.5$ Hz), 3.35 (dd, $J = 14.5, 8.5$ Hz), 3.30 (dd, $J = 14.5, 7.5$ Hz), and 3.19 (dd, $J = 14.5, 8.0$ Hz) (2H), 2.66–2.58 (m, 1H), 2.09–1.98 (m, 3H), 1.87–1.77 (m, 2H), 1.75–1.66 (m, 2H), 1.63–1.44 (m, 3H), 1.41–1.22 (m, 3H), 0.91 (s, 9H), 0.11 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 162.4, 162.1, 138.8, 138.3, 136.3, 135.9, 122.6, 121.9, 115.1, 114.6, 114.4, 51.3, 46.4, 43.1, 42.4, 42.2, 42.1, 35.8, 32.0, 31.8, 30.1, 28.7, 28.6, 26.7, 26.5, 26.1, 25.9, 25.7, 25.6, 24.9, 24.8, 18.2, –5.3; IR (film) ν (cm^{-1}) 2953, 2929, 2858, 1685, 1432, 1254, 1164, 1136; MS (EI) m/z (rel %): 390 [M^+] (1), 375 [$\text{M}^+ - \text{CH}_3$] (7), 333 [$\text{M} - \text{C}_6\text{H}_5$] $^+$ (100), 306 (17), 251 (58); HRMS (EI) calcd for $\text{C}_{22}\text{H}_{38}\text{N}_2\text{O}_2\text{Si}$ [M^+] 390.2702, found: 390.2705.

rel-(1S,6S)-10-(But-3-en-1-yl)-8-(cyanomethyl)-1-formyl-8-azabicyclo[4.3.1]dec-8-en-8-ium Trifluoromethanesulfonate (60). TiF_2O (13 μL , 77 μmol) was added to a solution of **59** (25 mg, 64 μmol) and DTBMP (14.5 mg, 70.4 μmol) in DCE (1.0 mL) at rt. After 20 min, the mixture was heated at 80 $^\circ\text{C}$ for 3 h. ^1H NMR analysis of an aliquot showed the formation of the iminium ion **60**: ^1H NMR (400 MHz, CDCl_3) characteristic signals δ (ppm) 9.99 (s) and 9.91 (s) (1H), 9.70 (s) and 9.45 (s) (1H), 6.24–6.05 (m, 1H), 5.90 (d, $J = 17.5$ Hz), 5.80 (d, $J = 17.5$ Hz), 5.68 (d, $J = 17.5$ Hz), and 5.57 (d, $J = 17.5$ Hz) (2H), 5.46–5.26 (m, 2H), 4.83 (d, $J = 5.5$ Hz), 4.27 (d, $J = 16.0$ Hz), 3.87 (d, $J = 14.0$ Hz), and 3.64 (bs) (2H), 3.20–2.98 (m, 2H), 2.81–1.54 (m, 12H).

N-(Cyanomethyl)-N-(5-methoxypent-4-en-1-yl)formamide (65). A solution of KHMDs (0.5 M in toluene, 7.68 mL, 3.84 mmol) was added dropwise to a solution of **64**^{9a} (499 mg, 3.49 mmol) in THF (14.0 mL) and DMF (7.0 mL) at rt. The reaction mixture was stirred for 1 h; then a solution of 18-crown-6 ether (1.01 g, 3.84 mmol) in THF (1.0 mL) and BrCH_2CN (345 μL , 5.18 mmol) were added. The solution was stirred for 18 h at rt; then saturated aqueous NaHCO_3 was added. The usual workup (EtOAc) and purification (60 to 70% EtOAc in hexanes) afforded a mixture of *E/Z* isomers and rotamers of **65** (238 mg, 38%) as a brown oil: ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.10 (s), 8.07 (s), and 8.05 (s) (1H), 6.30 (d, $J = 12.5$ Hz), and 5.95 (d, $J = 6.0$ Hz) (1H), 4.64 (dt, $J = 12.5, 7.5$ Hz, 1H), 4.27 (s), 4.26 (s), and 4.17 (s) (2H), 3.58 (s) and 3.50 (s) (3H), 3.48–3.37 (m) and 3.40 (t, $J = 7.0$ Hz) (2H), 2.07 (q, $J = 7.0$ Hz) and 1.97 (q, $J = 7.0$ Hz) (2H), 1.72–1.62 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 162.4 (d), 162.1 (d), 161.8 (d), 147.8 (d), 147.5 (d), 147.2 (d), 115.0 (s), 114.8 (s), 114.7 (s), 103.6 (d), 100.8 (d), 100.3 (d), 59.2 (q), 55.6 (q), 55.5 (q), 46.6 (t), 46.5 (t), 42.2 (t), 35.6 (t), 29.8 (t), 29.7 (t), 28.1 (t), 27.2 (t), 27.1 (t), 24.5 (t), 23.9 (t), 19.9 (t); IR (film) ν (cm^{-1}) 3059, 2937, 2856, 1681, 1429, 1397, 1209, 1181, 1143, 1108, 934; MS (EI) m/z (rel %): 182 [M^+] (10), 152 (9), 98 (100), 85 (29); HRMS (EI) calcd for $\text{C}_9\text{H}_{14}\text{N}_2\text{O}_2$ [M^+] 182.1055, found 182.1057.

rel-9-(Methoxymethylene)-1,3-dioxo-2-phenyldecahydro-1H-pyrrolo[3,4-*a*]indolizine-4-carbonitrile (67). TiF_2O (61 μL , 0.36 mmol, freshly distilled over P_2O_5) was added to a solution of **65** (60 mg, 0.33 mmol) and DTBMP (74 mg, 0.36 mmol) in DCM (5.0 mL) at rt. After 30 min, *N*-phenylmaleimide (342 mg, 1.97 mmol), followed by *i*-Pr₂NEt (230 μL , 1.32 mmol), was added at 0 $^\circ\text{C}$. The mixture was then stirred for 2 h at rt. Saturated aqueous Na_2CO_3 was added. The usual workup (DCM) and purification using silica gel saturated with Et₃N (20 to 60% EtOAc in hexanes) afforded two separable portions of two diastereomers of **67**: portion 1 (42 mg, 1.5:1 d.r.) as a yellow oil and portion 2 (34 mg, 2:1 d.r.) as a brown oil (79% global yield). Portion 1 (two diastereomers): ^1H NMR (300 MHz, CDCl_3) δ (ppm) 7.49–7.36 (m, 3H), 7.27–7.18 (m, 2H), 6.78 (s) and 6.36 (s) (1H), 4.41 (s), 3.80 (dd, $J = 9.5, 6.0$ Hz), and 3.64–3.49 (m) (3H), 3.65 (s) and 3.62 (s) (3H), 3.47–3.42 (m) and 3.39–3.31 (m) (1H), 3.04–2.76 (m, 2H), 2.45 (td, $J = 11.0, 2.5$ Hz) and 2.32 (td, $J = 11.0, 3.5$ Hz) (1H), 1.79–1.60 (m) and 1.58–1.46 (m) (3H); ^{13}C NMR (75.5 MHz, CDCl_3) δ (ppm) 175.0, 174.6, 174.4, 174.2, 145.9, 143.3, 131.9, 131.4, 129.6, 129.5, 129.3, 126.7, 126.5, 117.7, 115.4, 111.8, 108.4, 66.2, 63.4, 59.8, 59.6, 56.9, 54.7, 50.5, 48.8, 48.5,

48.1, 45.7, 45.1, 23.8, 23.0, 22.4, 21.5; IR (film) ν (cm^{-1}) 3019, 2942, 2831, 1716, 1498, 1386, 1181, 1129; MS (EI) m/z (rel %): 392 (21), 360 [MNa^+] (100), 333 (35); HRMS (EI) calcd for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_3\text{Na}$ [MNa^+] 360.1319, found 360.1327. Portion 2 (two diastereomers): ^1H NMR (300 MHz, CDCl_3) δ (ppm) 7.52–7.38 (m, 3H), 7.33–7.21 (m, 2H), 6.80 (s) and 6.25 (s) (1H), 4.44 (d, $J = 8.5$ Hz), 3.79 (t, $J = 9.0$ Hz), and 3.60–3.24 (m) (4H), 3.63 (s, 3H), 3.08–2.99 (m) and 2.94–2.81 (m) (2H), 2.65 (td, $J = 11.5, 2.5$ Hz) and 2.03 (t, $J = 11.0$ Hz) (1H), 1.84–1.50 (m, 3H); ^{13}C NMR (75.5 MHz, CDCl_3) δ (ppm) 174.9, 174.1, 173.5, 173.4, 145.8, 143.1, 131.9, 131.6, 129.6, 129.5, 129.4, 129.2, 126.9, 126.9, 115.4, 113.9, 112.4, 108.3, 66.4, 63.3, 59.8, 59.7, 56.9, 55.3, 51.4, 48.7, 46.8, 46.1, 45.5, 44.8, 23.6, 23.2, 22.3, 21.8; IR (film) ν (cm^{-1}) 3019, 2939, 2836, 1717, 1499, 1384, 1194, 1130; MS (EI) m/z (rel %): 392 (22), 360 [MNa^+] (100), 333 (29); HRMS (EI) calcd for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_3\text{Na}$ [MNa^+] 360.1319, found 360.1327.

N-(rel-(2S,3S)-2-Allyl-3-(2-(allyloxy)vinyl)-6-(benzyloxy)hexyl)formamide (76). TBAI (1.51 g, 4.09 mmol) and diformyl-imide sodium salt (1.16 g, 12.3 mmol) were added to a solution of **75**⁸ (1.61 g, 4.09 mmol) in DMF (41 mL). The solution was stirred at 50 $^\circ\text{C}$ for 24 h and then cooled at rt. 5% NaOH solution in MeOH (6.0 mL) was added, and the mixture was stirred at rt for 45 min. The usual workup (Et₂O) and purification using silica gel saturated with Et₃N (10 to 80% EtOAc in hexanes) afforded **76** (1.13 g, 78%) as a colorless oil: ^1H NMR (300 MHz, CDCl_3) δ (ppm) 8.10 (d, $J = 1.5$ Hz), 7.96 (d, $J = 12.0$ Hz), and 7.92 (d, $J = 12.0$ Hz) (1H), 7.37–7.25 (m, 5H), 6.17 (d, $J = 12.5$ Hz), 6.16 (d, $J = 12.5$ Hz), 6.10 (d, $J = 5.0$ Hz), and 6.08 (d, $J = 6.0$ Hz) (1H), 5.97–5.87 (m, 1H), 5.87–5.68 (m, 1H), 5.55 (bs, 1H), 5.35–5.21 (m, 2H), 5.09–5.02 (m, 2H), 4.56–4.46 (m), 4.49 (s), and 4.27–4.07 (m) (SH), 3.63 (ddd, $J = 13.0, 8.0, 4.5$ Hz), 3.48–3.34 (m), and 3.31–3.00 (m) (4H), 2.58–2.44 (m) and 2.22–1.86 (m) (3H), 1.71–1.13 (m, 5H); ^{13}C NMR (75.5 MHz, CDCl_3) δ (ppm) 164.7 (d), 161.2 (d), 146.9 (d), 146.7 (d), 145.5 (d), 145.4 (d), 138.2 (s), 136.6 (d), 136.5 (d), 136.4 (d), 136.0 (d), 133.4 (d), 133.2 (d), 128.0 (d), 127.3 (d), 127.2 (d), 117.6 (t), 117.2 (t), 117.1 (t), 116.9 (t), 116.7 (t), 116.4 (t), 116.2 (t), 108.6 (d), 108.4 (d), 104.9 (d), 104.4 (d), 72.5 (d), 72.3 (d), 70.0 (d), 69.8 (d), 69.6 (d), 43.3 (d), 42.5 (d), 42.4 (d), 42.0 (t), 39.1 (d), 38.7 (d), 38.5 (t), 38.4 (t), 35.0 (d), 34.7 (d), 34.2 (t), 33.9 (t), 33.4 (t), 33.0 (t), 29.2 (t), 29.1 (t), 28.9 (t), 27.5 (t), 27.3 (t), 27.1 (t); IR (film) ν (cm^{-1}) 3299, 3066, 3028, 2930, 2858, 1665, 1536, 1453, 1385, 1163, 1100; MS (CI: NH_3) m/z (rel %): 316 [$\text{M}^+ - \text{C}_3\text{H}_5$] (30), 208 (35), 163 (100); HRMS (CI: NH_3) calcd for $\text{C}_{22}\text{H}_{32}\text{NO}_3$ [MH^+] 358.2382, found 358.2390.

(((4-(2-(Allyloxy)vinyl)-5-methyleneoct-7-en-1-yl)oxy)methyl)benzene (77). NaH (60% in mineral oil, 24 mg, 0.58 mmol) was added to a solution of formamide (770 μL , 19.2 mmol) in THF (1.5 mL) and DMF (0.7 mL) at 0 $^\circ\text{C}$. The solution was stirred for 1 h at rt; then NaI (72 mg, 0.48 mmol) and a solution of **75** (175 mg, 0.445 mmol) in THF (1.5 mL) were added. The mixture was stirred for 48 h at 80 $^\circ\text{C}$; then water was added. The usual workup (EtOAc) and purification using silica gel saturated with Et₃N (0 to 60% EtOAc in hexanes) afforded **76** (56 mg, 35%) as a colorless oil and **77** (78 mg, 56%) as a colorless oil: **77**: ^1H NMR (300 MHz, CDCl_3) δ (ppm) 7.38–7.24 (m, 5H), 6.22 (d, $J = 12.5$ Hz) and 6.00 (d, $J = 6.5$ Hz) (1H), 5.97–5.73 (m, 2H), 5.32 (dd, $J = 17.0, 1.5$ Hz), 5.29 (dd, $J = 17.5, 1.5$ Hz), 5.23 (dd, $J = 8.0, 1.0$ Hz), and 5.20 (dd, $J = 10.5, 1.5$ Hz) (2H), 5.08 (m, 2H), 4.84–4.83 (m) and 4.77–4.75 (m) (2H), 4.66 (dd, $J = 12.5, 9.0$ Hz) and 4.27–4.18 (m) (3H), 4.50 (s, 2H), 3.47 (td, $J = 6.0, 5.0$ Hz, 2H), 3.24 (td, $J = 9.5, 4.5$ Hz) and 2.55–2.47 (m) (1H), 2.77 (t, $J = 7.5$ Hz, 2H), 1.70–1.35 (m, 4H); ^{13}C NMR (75.5 MHz, CDCl_3) δ (ppm) 151.1 (s), 150.9 (s), 146.1 (d), 144.7 (d), 138.6 (s), 138.5 (s), 136.6 (d), 136.5 (d), 133.9 (d), 133.4 (d), 128.2 (d), 127.5 (d), 127.3 (d), 117.2 (t), 116.8 (t), 116.1 (t), 115.9 (t), 109.8 (d), 109.5 (t), 108.9 (t), 107.4 (d), 72.7 (t), 72.4 (t), 70.3 (t), 70.2 (t), 69.8 (t), 44.3 (d), 40.0 (d), 39.0 (t), 38.6 (t), 30.3 (t), 30.1 (t), 27.6 (t), 27.5 (t); IR (film) ν (cm^{-1}) 3081, 3032, 2982, 2940, 2856, 1661, 1643, 1454; MS (EI) m/z (rel %): 312 [M^+] (2), 221 (8), 163 (100), 91 (100); HRMS (EI) calcd for $\text{C}_{21}\text{H}_{28}\text{O}_2$ [M^+] 312.2089, found 312.2084

Ethyl 2-(*N*-(*rel*-(2*S*,3*S*)-2-Allyl-3-(2-(allyloxy)vinyl)-6-(benzyl-oxy)hexyl)formamido)acetate (78). NaH (60% in mineral oil, 190 mg, 4.74 mmol) was added to a solution of **76** (1.13 g, 3.16 mmol) in THF (7.0 mL) and DMF (2.5 mL) at rt, and the solution was stirred for 1 h. BrCH₂CO₂Et (525 μL, 4.74 mmol) was added. The mixture was stirred for 18 h at rt; then water was added and THF was removed under reduced pressure. The usual workup (EtOAc) and purification (20 to 80% EtOAc in hexanes) afforded **78** (1.32 g, 94%) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.07 (s), 8.07 (s), and 8.06 (s) (1H), 7.37–7.25 (m, 5H), 6.16 (d, *J* = 12.5 Hz) and 6.06 (d, *J* = 6.5 Hz) (1H), 5.99–5.57 (m, 2H), 5.35–5.18 (m, 2H), 5.07–4.98 (m, 2H), 4.48 (s, 2H), 4.52–4.43 (m) and 4.22–3.84 (m) (7H), 3.44 (t, *J* = 6.0 Hz) and 3.43 (t, *J* = 6.0 Hz) (2H), 3.39–3.29 (m) and 3.23–3.06 (m) (2H), 2.67–2.59 (m), 2.25–2.22 (m), and 2.11–1.94 (m) (3H), 1.71–1.41 (m, 4H), 1.30–1.24 (m, 4H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 168.9 (s), 168.2 (s), 168.1 (s), 163.6 (d), 163.3 (d), 163.2 (d), 147.3 (d), 147.0 (d), 146.0 (d), 145.7 (d), 138.4 (s), 138.2 (s), 136.7 (d), 136.5 (d), 135.7 (d), 133.6 (d), 133.1 (d), 128.1 (d), 127.3 (d), 117.2 (t), 117.1 (t), 116.9 (t), 116.4 (t), 116.0 (t), 107.6 (d), 107.3 (d), 104.0 (d), 72.6 (t), 72.4 (t), 72.2 (t), 70.1 (t), 69.9 (t), 69.8 (t), 69.7 (t), 61.4 (t), 61.3 (t), 61.1 (t), 61.0 (t), 48.9 (t), 48.5 (t), 44.1 (t), 44.0 (t), 43.8 (t), 43.6 (t), 40.4 (d), 40.3 (d), 40.0 (d), 39.9 (d), 38.7 (d), 38.1 (d), 34.2 (d), 33.9 (d), 33.7 (t), 33.6 (t), 33.2 (t), 33.1 (t), 28.9 (t), 28.2 (t), 27.7 (t), 27.6 (t), 27.3 (t), 13.8 (q); IR (film) ν (cm⁻¹) 3073, 3035, 2986, 2936, 2861, 1749, 1679, 1453, 1435, 1197, 1098; MS (CI: NH₃) *m/z* (rel %): 444 [MH⁺] (100), 416 (13), 402 (16), 358 (23); HRMS (CI: NH₃) calcd for C₂₆H₃₈NO₅ [MH⁺] 444.2750, found 444.2757.

Ethyl 2-(*N*-(*rel*-(2*S*,3*S*)-2-Allyl-3-(3-(benzyloxy)propyl)-4-formylhept-6-en-1-yl)formamido)acetate (79). A solution of **78** (703 mg, 1.58 mmol) in toluene (31 mL) was heated at 150 °C in a sealed tube for 96 h. The solution was concentrated under reduced pressure to afford an inseparable mixture of diastereomers and rotamers of **79** (703 mg, 100%) as a pale yellow oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 9.70–9.61 (m, 1H), 8.08 (s) and 8.06 (s) (1H), 7.40–7.24 (m, 5H), 5.76–5.59 (m, 2H), 5.11–4.98 (m, 4H), 4.49 (s, 2H), 4.23–4.16 (m, 2H), 4.03 (d, *J* = 17.5 Hz), 4.01 (d, *J* = 17.5 Hz), 3.95–3.80 (m), 3.90 (d, *J* = 17.5 Hz), and 3.87 (d, *J* = 17.5 Hz) (2H), 3.60–3.38 (m), 3.31–3.17 (m), and 3.15–3.07 (m) (4H), 2.56–2.39 (m, 2H), 2.31–1.85 (m, 4H), 1.83–1.38 (m, 5H), 1.31–1.22 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 205.8 (d), 205.5 (d), 205.4 (d), 205.0 (d), 169.6 (s), 168.9 (s), 164.6 (d), 164.5 (d), 164.0 (d), 164.0 (d), 138.9 (s), 138.7 (s), 136.7 (d), 136.6 (d), 136.0 (d), 135.9 (d), 135.9 (d), 135.4 (d), 135.4 (d), 128.7 (d), 128.7 (d), 128.0 (d), 127.8 (d), 118.0 (t), 117.9 (t), 117.9 (t), 117.7 (t), 117.5 (t), 117.3 (t), 117.3 (t), 117.3 (t), 72.9 (t), 72.8 (t), 72.8 (t), 70.2 (t), 70.1 (t), 69.6 (t), 69.5 (t), 61.7 (t), 61.3 (t), 61.3 (t), 52.6 (d), 52.5 (d), 49.5 (t), 49.4 (t), 48.8 (t), 48.7 (t), 44.8 (t), 44.6 (t), 43.9 (t), 43.9 (t), 38.1 (d), 37.7 (d), 37.4 (d), 37.1 (d), 36.9 (d), 36.6 (d), 33.0 (t), 32.9 (t), 32.5 (t), 32.5 (t), 31.4 (t), 31.1 (t), 30.8 (t), 30.7 (t), 28.6 (t), 28.4 (t), 28.4 (t), 23.9 (t), 23.7 (t), 23.5 (t), 13.6 (q); IR (film) ν (cm⁻¹) 3073, 2982, 2936, 2864, 1748, 1720, 1678, 1436, 1400, 1198; MS (EI) *m/z* (rel %): 443 [M⁺] (3), 398 [M – OC₂H₅]⁺ (7), 342 (36), 264 (33), 116 (90), 91 (100); HRMS (EI) calcd for C₂₆H₃₇NO₅ [M⁺] 443.2672, found 443.2661.

Ethyl 2-(*N*-(*rel*-(1*S*,7*S*)-7-(3-(Benzyloxy)propyl)-6-formyl-cyclohept-3-en-1-yl)methyl)formamido)acetate (80). Second-generation Grubbs' catalyst (40 mg, 5 mol %) was added to a solution of **79** (423 mg, 0.954 mmol) in DCM (160 mL). The solution was stirred for 18 h at rt and then concentrated under reduced pressure. The usual purification (50% EtOAc in hexanes) afforded a mixture of diastereomers and rotamers of **80** (344 mg, 87%) as a brown oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 9.72 (s), 9.70 (s), 9.62 (s), and 9.61 (s) (1H), 8.11 (s), 8.07 (s), and 8.05 (s) (1H), 7.42–7.23 (m, 5H), 5.78–5.56 (m, 2H), 4.48 (s) and 4.45 (s) (2H), 4.24–4.11 (m), 4.07 (s), 3.98 (d, *J* = 17.0 Hz), 3.95 (s), and 3.90 (d, *J* = 17.0 Hz) (4H), 3.52–3.12 (m, 4H), 2.62–2.34 (m) and 2.33–2.16 (m) (4H), 2.12–1.77 (m, 3H), 1.71–1.30 (m, 4H), 1.28–1.22 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 205.8 (d), 205.1 (d), 204.9 (d), 204.6 (d), 169.7 (s), 169.7 (s), 168.9 (s), 168.9 (s), 164.4

(d), 164.3 (d), 163.9 (d), 163.8 (d), 138.8 (s), 138.7 (s), 131.3 (d), 130.8 (d), 129.2 (d), 129.0 (d), 128.7 (d), 128.6 (d), 128.6 (d), 128.6 (d), 128.5 (d), 128.3 (d), 127.9 (d), 127.9 (d), 127.8 (d), 127.8 (d), 127.7 (d), 72.9 (t), 72.8 (t), 72.7 (t), 72.6 (t), 70.2 (t), 70.2 (t), 69.6 (t), 69.6 (t), 61.7 (t), 61.6 (t), 61.3 (t), 61.2 (t), 56.6 (d), 56.3 (d), 52.4 (t), 51.7 (d), 51.6 (d), 51.0 (t), 49.2 (t), 48.2 (t), 47.9 (t), 46.0 (t), 44.4 (t), 43.5 (t), 41.9 (d), 41.6 (d), 38.6 (d), 38.0 (d), 37.2 (d), 37.1 (d), 34.3 (d), 34.2 (d), 28.5 (t), 28.2 (t), 28.1 (t), 28.0 (t), 27.5 (t), 27.0 (t), 27.0 (t), 26.9 (t), 23.7 (t), 23.6 (t), 23.4 (t), 23.2 (t), 22.6 (t), 22.4 (t), 20.7 (t), 20.6 (t), 13.6 (q), 13.6 (q); IR (film) ν (cm⁻¹) 2986, 2938, 2869, 1746, 1720, 1676, 1439, 1401, 1371, 1203; MS (EI) *m/z* (rel %): 416 [MH⁺] (17), 402 (10), 388 (45), 218 (100); HRMS (EI) calcd for C₂₄H₃₃NO₅ [M⁺] 415.2359, found 415.2361.

Ethyl 2-(*N*-(*rel*-(1*S*,7*S*)-7-(3-(Benzyloxy)propyl)-6-(((*tert*-butyldimethylsilyloxy)methylene)cyclohept-3-en-1-yl)-methyl)formamido)acetate (81). Following the procedure used to prepare **40**, a solution of **80** (49 mg, 0.12 mmol) in DCM (2.0 mL) was treated with TBDMSOTf (65 μL, 0.28 mmol) and *i*-Pr₂NEt (49 μL, 0.28 mmol) for 18 h at rt to afford, after the usual purification using silica gel saturated with Et₃N (0 to 40% EtOAc in hexanes), one geometrical isomer of **81** (as a mixture of rotamers) of unidentified stereochemistry (48 mg, 76%) as a colorless oil: ¹H NMR (400 MHz, C₆D₆) δ (ppm) 7.96 (s) and 7.81 (s) (1H), 7.43–7.32 (m, 2H), 7.27–7.07 (m, 3H), 6.23 (s, 1H), 5.81–5.73 (m, 1H), 5.58–5.44 (m, 1H), 4.42–4.34 (AB quartet, 2H), 3.95–3.79 (m), 3.72 (d, *J* = 17.0 Hz), and 3.46–3.22 (m) (7H), 3.55 (dd, *J* = 14.0, 7.0 Hz), 3.12 (dd, *J* = 14.0, 7.5 Hz), 2.85 (dd, *J* = 14.5, 7.5 Hz), and 2.76–2.62 (m) (3H), 2.21–2.12 (m, 1H), 1.84–1.31 (m, 6H), 1.28–1.15 (m, 1H), 0.94 (s, 9H), 0.88 (t, *J* = 7.0 Hz, 3H), 0.07 (s, 6H); ¹³C NMR (100 MHz, C₆D₆) δ (ppm) 169.5 (s), 168.8 (s), 163.6 (d), 163.4 (d), 139.8 (s), 139.5 (s), 135.2 (d), 134.8 (d), 129.7 (d), 129.5 (d), 128.6 (d), 128.5 (d), 128.3 (d), 128.2 (d), 128.0 (d), 127.8 (d), 127.7 (d), 127.5 (d), 122.2 (s), 121.1 (s), 72.7 (t), 72.5 (t), 70.3 (t), 69.5 (t), 60.8 (t), 60.6 (t), 50.7 (t), 48.2 (t), 46.6 (t), 44.0 (t), 43.9 (t), 42.7 (d), 40.5 (d), 40.1 (d), 28.6 (t), 28.2 (t), 27.6 (t), 27.2 (t), 25.4 (q), 25.2 (q), 24.6 (t), 24.5 (t), 21.6 (t), 21.2 (t), 17.8 (s), 13.3 (q), –6.1 (q), –6.1 (q); IR (film) ν (cm⁻¹) 3024, 2952, 2930, 2857, 1751, 1682, 1435, 1253, 1198, 838; MS (ESI) *m/z* (rel %): 552 [MNa⁺] (100); HRMS (ESI) calcd for C₃₀H₄₇NO₅SiNa [MNa⁺] 552.3116, found 552.3127.

Ethyl 2-(*N*-(*rel*-(1*S*,2*S*)-3-(((*tert*-Butyldimethylsilyloxy)-methylene)-2-(3-hydroxypropyl)cycloheptyl)methyl)formamido)acetate (82). A mixture of **81** (89 mg, 0.17 mmol) and Pd(OH)₂/C (20%, 12 mg, 10 mol %) in MeOH (5.0 mL) was stirred under a hydrogen atmosphere for 2.5 h. The mixture was filtered on Celite and concentrated under reduced pressure. The usual purification (40 to 100% EtOAc in hexanes) afforded a mixture of rotamers of **82** (52 mg, 70%) as a colorless oil: ¹H NMR (400 MHz, C₆D₆) δ (ppm) 8.09 (s) and 7.78 (s) (1H), 6.30 (s, 1H), 3.92 (q, *J* = 7.0 Hz), 3.89–3.78 (m), 3.36 (d, *J* = 17.5 Hz), and 3.26 (d, *J* = 17.5 Hz) (4H), 3.73–3.61 (m) and 3.59–3.44 (m) (2H), 3.02 (dd, *J* = 14.5, 8.5 Hz), 2.92–2.81 (m), and 2.74 (dd, *J* = 14.5, 7.0 Hz) (2H), 2.26 (bs) and 2.18–2.05 (m) (2H), 1.85–1.49 (m, 5H), 1.47–1.11 (m, 6H), 1.02–0.86 (m), 0.96 (s), and 0.92 (t, *J* = 7.0 Hz) (14H), 0.09 (s, 6H); ¹³C NMR (100 MHz, C₆D₆) δ (ppm) 169.5 (s), 168.9 (s), 164.4 (d), 163.9 (d), 136.4 (d), 136.2 (d), 123.9 (s), 123.3 (s), 61.5 (t), 61.0 (t), 60.9 (t), 60.6 (t), 51.7 (t), 48.2 (t), 47.0 (t), 44.0 (t), 43.0 (d), 42.9 (d), 42.1 (d), 41.7 (d), 30.7 (t), 30.6 (t), 28.8 (t), 28.3 (t), 26.9 (t), 26.6 (t), 25.6 (t), 25.6 (t), 25.2 (q), 24.7 (t), 24.5 (t), 21.8 (t), 21.3 (t), 17.7 (s), 13.3 (q), 13.3 (q), –6.0 (q), –6.1 (q); IR (film) ν (cm⁻¹) 3592–3188, 2930, 2858, 1751, 1675, 1442, 1401, 1253, 1198; MS (ESI) *m/z* (rel %): 464 [MNa⁺] (100); HRMS (ESI) calcd for C₂₃H₄₃NO₅SiNa [MNa⁺] 464.2830, found 464.2809.

(2*Z*)-Methyl 5-(*rel*-(1*S*,7*S*)-2-(((*tert*-Butyldimethylsilyloxy)-methylene)-7-((*N*-(2-ethoxy-2-oxoethyl)formamido)methyl)-cycloheptyl)pent-2-enoate (83). Oxalyl chloride (19 μL, 0.22 mmol) was added to a solution of DMSO (27 μL, 0.40 mmol) in DCM (1.0 mL) at –78 °C. After 10 min at –78 °C, a solution of **82** (89 mg, 0.20 mmol) in DCM (3.0 mL) was added, and the mixture was stirred 45 min at –78 °C. Et₃N (141 μL, 1.01 mmol) was added, and the reaction mixture was allowed to warm up to rt over 2 h.

Saturated aqueous NaHCO₃ was added; then the usual workup (DCM) afforded the corresponding aldehyde (90 mg of crude material). A solution of KHMDS (0.5 M in toluene, 0.40 mL, 0.20 mmol) was added to a solution of methyl bis(2,2,2-trifluoroethyl)-phosphonoacetate (67 mg, 0.20 mmol) and 18-crown-6 ether (133 mg, 0.505 mmol) in THF (2.0 mL) at -78 °C. After 30 min at -78 °C, a solution of crude aldehyde (90 mg of crude material) in THF (2.0 mL) was added and the reaction mixture was allowed to warm up to rt over 2 h. Saturated aqueous NaHCO₃ was added. The usual workup (DCM) and purification (5 to 15% acetone in toluene) afforded a mixture of rotamers of **83** (65 mg, 65% over 2 steps) as a pale yellow oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.09 (s, 1H), 6.26–6.18 (m, 1H), 6.09 (s) and 6.06 (s) (1H), 5.77 (d, *J* = 11.5 Hz) and 5.74 (d, *J* = 11.5 Hz) (1H), 4.21 (q, *J* = 7.0 Hz) and 4.19 (q, *J* = 7.0 Hz) (2H), 4.05 (d, *J* = 17.5 Hz), 3.98 (d, *J* = 17.5 Hz), 3.96 (d, *J* = 17.5 Hz), and 3.89 (d, *J* = 17.5 Hz) (2H), 3.69 (s) and 3.68 (s) (3H), 3.35 (dd, *J* = 14.0, 7.5 Hz), 3.26 (dd, *J* = 14.5, 7.5 Hz), and 3.15 (dd, *J* = 14.5, 8.0 Hz) (2H), 2.60 (ddd, *J* = 16.5, 9.0, 5.5 Hz, 1H), 2.49 (q, *J* = 7.5 Hz, 2H), 2.15–2.02 (m) and 1.99–1.93 (m) (2H), 1.74–1.45 (m, 6H), 1.42–1.21 (m), 1.28 (t, *J* = 7.0 Hz), and 1.26 (t, *J* = 7.0 Hz) (6H), 0.91 (s, 9H), 0.11 (s), 0.11 (s), and 0.10 (s) (6H); ¹³C NMR (100 MHz, C₆D₆) δ (ppm) 169.6 (s), 168.9 (s), 166.7 (s), 166.6 (s), 163.6 (d), 163.3 (d), 151.3 (d), 150.4 (d), 136.5 (d), 136.3 (d), 123.4 (s), 122.8 (s), 120.0 (d), 119.5 (d), 60.8 (t), 60.6 (t), 51.5 (t), 50.2 (q), 50.0 (q), 48.1 (t), 46.7 (t), 44.0 (t), 43.6 (d), 43.1 (d), 42.6 (d), 42.5 (d), 28.7 (t), 28.2 (t), 27.5 (t), 27.2 (t), 26.8 (t), 26.4 (t), 26.0 (t), 25.6 (t), 25.3 (q), 25.2 (q), 24.8 (t), 17.7 (s), 13.3 (q), -6.0 (q), -6.1 (q); IR (film) ν (cm⁻¹) 3024, 2950, 2929, 2857, 1752, 1723, 1682, 1646, 1437, 1254, 1197, 1167, 837; MS (ESI) *m/z* (rel %): 518 [MNa⁺] (100); HRMS (ESI) calcd for C₂₆H₄₅NO₆SiNa [MNa⁺] 518.2908, found 518.2910.

Oxazolium Ion 86. Tf₂O (4.3 μL, 26 μmol) was added to a solution of **83** (11.5 mg, 23.2 μmol) and DTBMP (5.2 mg, 26 μmol) in CDCl₃ (0.6 mL) at rt. After 5 min, ¹H NMR analysis showed the formation of oxazolium ion **86**: ¹H NMR (300 MHz, CDCl₃) characteristic signals δ (ppm) 9.60 (s, 1H), 7.26 (d, 1H, *J* = 2.0 Hz), 6.33 (dt, *J* = 11.5, 8.0 Hz, 1H), 6.04 (s, 1H), 5.78 (d, *J* = 11.5 Hz, 1H), 4.42 (qd, *J* = 7.0, 2.0 Hz, 2H), 4.25 (d, *J* = 7.5 Hz, 2H), 3.68 (s, 3H), 2.70–2.48 (m, 2H), 2.39–2.27 (m, 1H), 2.13–2.01 (m, 2H), 1.98–1.90 (m, 1H), 1.73–1.02 (m, 8H), 1.49 (t, *J* = 7.0 Hz, 3H), 0.89 (s, 9H), 0.10 (s), and 0.09 (s) (6H).

***N*-(rel-(2S,3S)-2-Allyl-3-(2-(allyloxy)vinyl)-6-(benzyloxy)-hexyl)-*N*-(cyanomethyl)formamide (87).** NH₃ gas was condensed (60 mL) in a solution of **75** (1.52 g, 3.86 mmol) in THF (15 mL) in a sealed tube at -78 °C. The tube was sealed, and the solution was stirred for 72 h at rt and then cooled at -78 °C to decrease pressure. The sealed tube was opened, and the mixture was allowed to warm up to rt. After complete NH₃ evaporation, saturated aqueous NaHCO₃ was added and THF was removed under reduced pressure. Water was added; then the usual workup (EtOAc) afforded a mixture of *E/Z* isomers and rotamers of the corresponding primary amine (1.27 g, 100%) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.34–7.23 (m, 5H), 6.14 (d, *J* = 12.5 Hz) and 6.04 (d, *J* = 6.5 Hz) (1H), 5.99–5.69 (m, 2H), 5.34–5.17 (m, 2H), 5.08–4.98 (m, 2H), 4.53 (dd, *J* = 12.5, 10.0 Hz) and 4.11 (dd, *J* = 10.5, 6.5 Hz) (1H), 4.49 (s, 2H), 4.22–4.17 (m, 2H), 3.46 (t, *J* = 6.0 Hz) and 3.44 (t, *J* = 6.0 Hz) (2H), 2.79–2.48 (m, 2H), 2.19–2.04 (m, 2H), 1.97–1.89 (m) and 1.71–1.20 (m) (6H). BrCH₂CN (270 μL, 4.05 mmol) was added to a solution of primary amine (1.27 g, 3.86 mmol) and *i*-Pr₂NEt (0.71 mL, 4.1 mmol) in THF (70 mL). The solution was stirred for 18 h at rt. Water was added, and THF was removed under reduced pressure. Saturated aqueous NaHCO₃ was added; then the usual workup (EtOAc) afforded a mixture of *E/Z* isomers and rotamers of the secondary amine (1.46 g) as a yellow oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.38–7.23 (m, 5H), 6.16 (d, *J* = 12.5 Hz) and 6.07 (d, *J* = 6.5 Hz) (1H), 6.00–5.67 (m, 2H), 5.35–5.19 (m, 2H), 5.07–4.99 (m, 2H), 4.53 (dd, *J* = 12.5, 10.0 Hz) and 4.12 (dd, *J* = 10.5, 6.5 Hz) (1H), 4.49 (s, 2H), 4.23 (d, *J* = 5.5 Hz) and 4.20 (d, *J* = 5.5 Hz) (2H), 3.60–3.41 (m, 4H), 2.78–2.49 (m, 2H), 2.23–2.09 (m, 2H), 2.00–1.90 (m) and 1.73–1.43 (m) (5H), 1.38–1.19 (m, 2H). A

solution of secondary amine (1.42 g, 3.86 mmol) in THF (84 mL) was treated with *N*-formylbenzotriazole (738 mg, 5.02 mmol). The mixture was stirred for 20 h at rt; then aqueous NaOH (2 N) was added. The solution was stirred for 15 min at rt; then water was added and THF was removed under reduced pressure. The usual workup (DCM) and purification (0 to 40% EtOAc in hexanes) afforded a mixture of *E/Z* isomers and rotamers of **87** (1.02 g, 67% over 3 steps) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.11 (s) and 8.00 (s) (1H), 7.38–7.26 (m, 5H), 6.19 (d, *J* = 12.5 Hz) and 6.08 (d, *J* = 6.5 Hz) (1H), 6.00–5.84 (m, 1H), 5.75–5.60 (m, 1H), 5.36–5.21 (m, 2H), 5.11–5.03 (m, 2H), 4.53–4.46 (m, 1H), 4.49 (s, 2H), 4.37–4.04 (m, 4H), 3.47–3.13 (m, 2H), 3.45 (t, *J* = 6.0 Hz, 2H), 2.64–2.55 (m), and 2.17–1.95 (m) (3H), 1.80–1.65 (m, 2H), 1.63–1.44 (m, 2H), 1.40–1.24 (m, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 162.6 (d), 162.5 (d), 162.4 (d), 147.5 (d), 147.2 (d), 146.1 (d), 138.3 (s), 138.3 (s), 136.2 (d), 136.0 (d), 135.2 (d), 135.1 (d), 133.5 (d), 133.1 (d), 128.1 (d), 127.4 (d), 127.3 (d), 117.5 (t), 117.3 (t), 117.2 (t), 116.8 (t), 114.5 (s), 107.3 (d), 103.8 (d), 72.6 (t), 72.5 (t), 70.0 (t), 69.6 (t), 48.7 (t), 48.5 (t), 43.7 (t), 43.2 (t), 39.9 (d), 39.6 (d), 38.8 (d), 38.2 (d), 35.8 (t), 35.4 (t), 35.3 (t), 34.1 (d), 33.8 (d), 33.6 (t), 33.3 (t), 33.0 (t), 32.8 (t), 30.2 (t), 29.8 (t), 28.8 (t), 27.8 (t), 27.6 (t), 27.5 (t), 27.3 (t); IR (film) ν (cm⁻¹) 3077, 3032, 2937, 2861, 1681, 1428, 1163, 1096, 920; MS (EI) *m/z* (rel %) 355 [M⁺ - C₃H₅] (2), 311 (10), 247 (19), 163 (62), 91 (100); HRMS (EI) calcd for C₂₄H₃₂N₂O₃ [M⁺] 396.2413, found 396.2417.

***N*-(rel-(2S,3S)-2-Allyl-3-(3-(benzyloxy)propyl)-4-formylhept-6-enyl)-*N*-(cyanomethyl)formamide (88).** A solution of **87** (1.40 g, 3.53 mmol) in toluene (75 mL) was heated at 150 °C in a sealed tube for 120 h. The solution was concentrated under reduced pressure. The usual purification using silica gel saturated with Et₃N (30 to 40% EtOAc in hexanes) afforded an inseparable mixture of diastereomers and rotamers of **88** (1.15 g, 82%) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 9.66 (d, *J* = 2.0 Hz) and 9.63 (d, *J* = 2.5 Hz) (1H), 8.08 (s), 8.07 (s), 7.97 (s), and 7.96 (s) (1H), 7.36–7.26 (m, 5H), 5.77–5.60 (m, 2H), 5.11–5.03 (m, 4H), 4.48 (s) and 4.47 (s) (2H), 4.28–4.01 (m, 2H), 3.49–3.42 (m, 2H), 3.26 (t, *J* = 7.0 Hz, 2H), 2.52–2.41 (m, 2H), 2.35–2.05 (m, 2H), 1.99–1.80 (m, 3H), 1.70–1.41 (m, 4H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 205.0 (d), 204.8 (d), 204.4 (d), 204.0 (d), 162.5 (d), 138.3 (s), 138.1 (s), 135.8 (d), 135.1 (d), 134.7 (d), 128.3 (d), 127.6 (d), 127.4 (d), 117.9 (t), 117.7 (t), 117.5 (t), 117.4 (t), 117.2 (t), 114.5 (s), 72.9 (t), 72.7 (t), 70.0 (t), 70.0 (t), 69.7 (t), 69.4 (t), 52.4 (d), 52.3 (d), 52.0 (d), 49.2 (t), 49.1 (t), 44.4 (t), 44.2 (t), 37.8 (d), 37.4 (d), 37.0 (d), 36.7 (d), 36.6 (d), 36.3 (d), 35.8 (t), 33.1 (t), 32.9 (t), 32.8 (t), 32.7 (t), 31.7 (t), 31.2 (t), 31.0 (t), 30.1 (t), 28.7 (t), 28.4 (t), 28.3 (t), 23.9 (t), 23.8 (t), 23.6 (t), 23.5 (t); IR (film) ν (cm⁻¹) 3073, 2936, 2863, 1719, 1681, 1430, 1101, 918; MS (EI) *m/z* (rel %) 396 [M⁺] (2), 367 [M⁺ - CHO] (7), 328 (15), 277 (18), 91 (100); HRMS (EI) calcd for C₂₄H₃₂N₂O₃ [M⁺] 396.2413, found 396.2401.

***N*-(rel-(1S,7S)-7-(3-(Benzyloxy)propyl)-6-formylcyclohept-3-en-1-yl)methyl)-*N*-(cyanomethyl)formamide (89).** Second-generation Grubbs' catalyst (41 mg, 5 mol %) was added to a solution of **88** (381 mg, 0.961 mmol) in DCM (160 mL). The solution was stirred for 18 h at rt and then concentrated under reduced pressure. The usual purification (20 to 50% EtOAc in hexanes) afforded an inseparable mixture of diastereomers and rotamers of **89** (303 mg, 86%) as a brown oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 9.71 (s), 9.65 (s), and 9.63 (s) (1H), 8.17 (s), 8.09 (s), 8.01 (s), and 8.00 (s) (1H), 7.38–7.26 (m, 5H), 5.83–5.61 (m, 2H), 4.57 (d, *J* = 17.5 Hz), 4.19 (d, *J* = 17.5 Hz), 4.08 (d, *J* = 17.5 Hz), and 4.60–4.06 (m) (2H), 4.49 (s) and 4.47 (s) (2H), 3.78 (dd, *J* = 14.0, 10.0 Hz), 3.49–3.34 (m), 3.32–3.20 (m), and 3.07 (dd, *J* = 14.0, 6.0 Hz) (4H), 2.62–2.50 (m, 2H), 2.43–2.15 (m), 2.10–2.00 (m), 1.83 (dd, *J* = 14.0, 7.0 Hz), and 1.77–1.32 (m) (9H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 205.6 (d), 204.5 (d), 203.8 (d), 203.4 (d), 162.6 (d), 162.4 (d), 162.2 (d), 138.2 (s), 131.3 (d), 130.7 (d), 129.1 (d), 128.3 (d), 128.0 (d), 127.6 (d), 127.5 (d), 114.7 (s), 114.6 (s), 72.9 (t), 72.9 (t), 72.7 (t), 70.3 (t), 70.2 (t), 69.5 (t), 56.5 (d), 56.0 (d), 51.7 (t), 51.3 (d), 50.0 (t), 47.4 (t), 44.8 (t), 43.7 (d), 41.5 (d), 41.1 (d), 38.5 (d), 38.2 (d), 36.3 (d), 36.1 (d), 35.3 (t), 33.7 (d), 33.5 (d), 30.5 (t), 29.6 (t), 28.8 (t), 28.4

(t), 28.2 (t), 27.6 (t), 27.1 (t), 27.1 (t), 24.1 (t), 23.9 (t), 23.7 (t), 22.4 (t), 22.1 (t), 21.2 (t), 21.0 (t); IR (film) ν (cm⁻¹) 3028, 2940, 2868, 1719, 1678, 1435, 1180, 1097; MS (EI) m/z (rel %) 368 [M⁺] (5), 340 (3), 277 (8), 91 (100); HRMS (EI) calcd for C₂₂H₂₈N₂O₃ [M⁺] 368.2100, found 368.2108.

***N*-(*rel*-(1*S*,7*S*,*E*)-7-(3-(Benzyloxy)propyl)-6-((*tert*-butyldimethylsilyloxy)methylene)cyclohept-3-enyl)methyl)-*N*-(cyanomethyl)formamide (*E*-90) and *N*-(*rel*-(1*S*,7*S*,*Z*)-7-(3-(Benzyloxy)propyl)-6-((*tert*-butyldimethylsilyloxy)methylene)cyclohept-3-enyl)methyl)-*N*-(cyanomethyl)formamide (*Z*-90).** Following the procedure used to prepare 40, a solution of 89 (304 mg, 0.825 mmol) in DCM (16.5 mL) was treated with TBDMSOTf (284 μ L, 1.24 mmol) and *i*-Pr₂N₂Et (287 μ L, 1.65 mmol) for 18 h at rt to afford, after the usual purification using silica gel saturated with Et₃N (0 to 40% EtOAc in hexanes), *E*-90 (187 mg) and *Z*-90⁵⁴ (63 mg) (63% global yield) as colorless oils. *E*-90 and *Z*-90 both exist as a mixture of rotamers and were separated at this stage. However, due to the instability of the products, full characterization was not possible and both isomers were carried through the sequence separately. Only the sequence with the major isomer *E*-90 is reported thereafter: *E*-90 (major) ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.14 (s) and 8.00 (s) (1H), 7.38–7.28 (m, 5H), 6.05 (s, 1H), 5.82–5.75 (m, 1H), 5.57–5.52 (m, 1H), 4.49 (s, 2H), 4.32 (d, J = 17.5 Hz, 1H), 4.14 (d, J = 17.5 Hz, 1H), 3.46 (t, J = 5.5 Hz, 2H), 3.33–3.19 (m, 2H), 3.10 (dd, J = 17.5, 6.5 Hz, 1H), 2.70–2.64 (m, 1H), 2.12–1.92 (m, 4H), 1.71–1.56 (m, 2H), 1.49–1.34 (m, 2H), 0.91 (s, 9H), 0.11 (s, 6H). *Z*-90 (minor) ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.14 (s) and 8.02 (s) (1H), 7.38–7.28 (m, 5H), 6.13 (s) and 6.10 (s) (1H), 5.71–5.65 (m, 1H), 5.57–5.50 (m, 1H), 4.59 (d, J = 17.5 Hz, 1H), 4.49 (s, 2H), 4.19 (d, J = 2.0 Hz) and 4.09 (d, J = 17.5 Hz) (1H), 3.45 (t, J = 6.0 Hz, 2H), 3.38–3.23 (m, 2H), 2.99–2.95 (m, 1H), 2.79–2.73 (m, 1H), 2.47 (dd, J = 18.0, 7.0 Hz, 1H), 2.09–1.88 (m, 3H), 1.68–1.27 (m, 4H), 0.90 (s, 9H), 0.12 (s) and 0.11 (s) (6H).

***N*-(*rel*-(1*S*,7*S*,*E*)-6-((*tert*-butyldimethylsilyloxy)methylene)-7-(3-hydroxypropyl)cyclohept-3-enyl)methyl)-*N*-(cyanomethyl)formamide (*E*-91).** A solution of Me₂BBr (1.0 M in DCM, 3.87 mL, 3.87 mmol) was added to a solution of *E*-90 (187 mg, 0.387 mmol) and DTBMP (795 mg, 3.87 mmol) in DCM (8.0 mL) at –25 °C. The solution was stirred for 2 h at –25 °C; then saturated aqueous NaHCO₃ (2.0 mL) was added at –25 °C. The mixture was stirred for 15 min at rt, and saturated aqueous NaCl was added. The usual workup (DCM) and purification using silica gel saturated with Et₃N (10 to 100% EtOAc in hexanes) afforded a mixture of rotamers of *E*-91 (110 mg, 72%) as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.19 (s) and 8.03 (s) (1H), 6.07 (s) and 6.04 (s) (1H), 5.80–5.74 (m, 1H), 5.56–5.52 (m, 1H), 4.31 (d, J = 17.5 Hz), 4.17 (d, J = 17.5 Hz), and 4.17 (d, J = 3.3 Hz) (2H), 3.63–3.57 (m, 2H), 3.33 (dd, J = 14.5, 7.0 Hz, 1H), 3.24 (dd, J = 14.5, 8.0 Hz, 1H), 3.11 (dd, J = 17.5, 6.5 Hz, 1H), 2.65–2.63 (m) and 2.54–2.49 (m) (1H), 2.12–2.05 (m, 2H), 2.00–1.89 (m) and 1.78 (bs) (3H), 1.61–1.54 (m, 2H), 1.43–1.36 (m, 2H), 0.90 (s, 9H), 0.11 (s) and 0.10 (s) (6H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 162.8 (d), 162.6 (d), 135.0 (d), 134.7 (d), 130.1 (d), 129.3 (d), 126.9 (d), 126.4 (d), 121.0 (s), 119.6 (s), 114.5 (s), 62.1 (t), 61.7 (t), 50.2 (t), 46.3 (t), 43.5 (d), 42.3 (d), 40.3 (d), 39.6 (d), 36.0 (t), 30.3 (t), 30.2 (t), 30.0 (t), 29.0 (t), 28.6 (t), 25.6 (q), 25.1 (t), 24.5 (t), 21.8 (t), 20.2 (t), 18.2 (s), –5.3 (q), –5.4 (q); IR (film) ν (cm⁻¹) 3611–3132, 2956, 2930, 2889, 2859, 1673, 1465, 1433, 1402, 1253, 1179; MS (EI) m/z (rel %) 392 [M⁺] (10), 335 [M⁺ – C₄H₉] (17), 249 (34), 74 (100); HRMS (EI) calcd for C₂₁H₃₆N₂O₃Si [M⁺] 392.2495, found 392.2503.

(*Z*)-Methyl 5-(*rel*-(1*S*,7*S*,*E*)-2-((*tert*-butyldimethylsilyloxy)methylene)-7-(*N*-(cyanomethyl)formamido)methyl)cyclohept-4-enyl)pent-2-enoate (*E*-92). Following the procedure used to prepare 83, a solution of *E*-91 (350 mg, 0.891 mmol) in DCM (6.0 mL) was added to a solution of oxalyl chloride (101 μ L, 1.16 mmol) and DMSO (127 μ L, 1.78 mmol) in DCM (12 mL), and the mixture was then treated with Et₃N (621 μ L, 4.46 mmol) to afford the corresponding aldehyde (350 mg of crude material). A solution of crude aldehyde in THF (6.0 mL) was then added to a solution of KHMDS (0.5 M in toluene, 1.78 mL, 0.891 mmol), methyl bis(2,2,2-trifluoroethyl)phosphonoacetate (298 mg, 0.891 mmol), and 18-

crown-6 ether (588 mg, 2.23 mmol) in THF (12 mL) to afford, after the usual workup (Et₂O) and purification (5 to 15% acetone in toluene), a mixture of rotamers of *E*-92 (188 mg, 47% over 2 steps) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.18 (s) and 8.04 (s) (1H), 6.26 (dt, J = 11.5, 8.0 Hz, 1H), 6.06 (s, 1H), 5.82–5.79 (m, 2H), 5.56–5.51 (m, 1H), 4.38 (d, J = 17.5 Hz, 1H), 4.12 (d, J = 17.5 Hz, 1H), 3.70 (s, 3H), 3.34–3.23 (m, 2H), 3.02 (dd, J = 17.0, 6.0 Hz, 1H), 2.84–2.79 (m, 1H), 2.66–2.60 (m, 1H), 2.54–2.48 (m, 1H), 2.20–2.16 (m, 1H), 2.09–2.02 (m, 3H), 1.73–1.65 (m, 1H), 1.49–1.40 (m, 1H), 0.91 (s, 9H), 0.12 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) major rotamer δ (ppm) 166.6 (s), 162.7 (d), 149.5 (d), 135.1 (d), 130.4 (d), 126.3 (d), 120.0 (d), 119.2 (s), 114.6 (s), 51.1 (q), 49.5 (t), 44.5 (d), 38.6 (d), 30.3 (t), 28.8 (t), 27.1 (t), 26.2 (t), 25.8 (t), 25.6 (q), 18.3 (s), –5.3 (q), –5.3 (q); IR (film) ν (cm⁻¹) 2952, 2928, 2857, 1720, 1680, 1462, 1437, 1406, 1254, 1198, 1177, 1154; MS (ESI) m/z (rel %) 469 [MNa⁺] (100), 353 (12), 130 (7); HRMS (ESI) calcd for C₂₄H₃₈N₂NaO₄Si [MNa⁺] 469.2498, found 469.2488.

***rel*-(4*R*,5*S*)-4-(2-(Allyloxy)vinyl)-5-(bromomethyl)oct-7-en-1-ol (93).** TMSI (11.2 mL, 78.5 mmol) was added to a solution of 75 (3.94 g, 8.73 mmol) and *i*-Pr₂N₂Et (18.2 mL, 105 mmol) in DCM (85 mL) at 0 °C. The solution was stirred for 18 h at rt; then water was added. The layers were separated, and the aqueous phase was extracted with EtOAc. Combined organic phases were washed twice with aqueous HCl (0.2 N) and with saturated aqueous NaCl, then dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was dissolved in MeOH (85 mL), and K₂CO₃ (2.41 g, 17.5 mmol) was added at 0 °C. The solution was stirred for 15 min at 0 °C; then water was added and MeOH was removed under reduced pressure. The usual workup (EtOAc, washed with brine) and purification using silica gel saturated with Et₃N (0 to 30% EtOAc in hexanes) afforded a mixture of *E*/*Z* isomers of 93 (2.19 g, 91%) as a yellow pale oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 6.24 (d, J = 12.5 Hz) and 6.08 (d, J = 6.5 Hz) (1H), 6.01–5.85 (m, 1H), 5.83–5.64 (m, 1H), 5.38–5.14 (m, 2H), 5.11 (d, J = 15.5 Hz) and 5.07 (d, J = 9.5 Hz) (2H), 4.47 (dd, J = 12.5, 10.5 Hz) and 4.09 (dd, J = 10.0, 6.5 Hz) (1H), 4.28–4.16 (m, 2H), 3.70–3.58 (m, 2H), 3.54 (dd, J = 10.0, 4.0 Hz) and 3.43–3.32 (m) (2H), 2.79–2.66 (m) and 2.09–1.95 (m) (1H), 2.35–2.11 (m, 2H), 1.76–1.18 (m, 6H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) major isomer: 147.0 (d), 135.9 (d), 133.2 (d), 117.3 (t), 117.0 (t), 105.0 (d), 69.9 (t), 62.3 (t), 43.9 (d), 39.7 (d), 37.3 (t), 33.9 (t), 30.4 (t), 28.5 (t); minor isomer: 145.9 (d), 135.7 (d), 133.7 (d), 117.3 (t), 117.0 (t), 107.6 (d), 72.4 (t), 62.5 (t), 44.4 (d), 36.9 (t), 35.5 (d), 33.9 (t), 30.2 (t), 28.4 (t); IR (film) ν (cm⁻¹) 3616–3172, 3077, 3017, 2921, 2867, 1664, 1644, 1455, 1425, 1161, 921; MS (ESI) m/z (rel %) 327 [MNa⁺] (92, ⁸¹Br), 325 [MNa⁺] (100, ⁷⁹Br); HRMS (ESI) calcd for C₁₄H₂₃⁷⁹BrO₂Na [MNa⁺] 325.0774, found 325.0779.

***N*-(*rel*-(2*S*,3*S*)-2-Allyl-3-(2-(allyloxy)vinyl)-6-hydroxyhexyl)-*N*-(cyanomethyl)formamide (94).** Following the procedure used to prepare 87, a solution of 93 (773 mg, 2.55 mmol) in THF (6.0 mL) was treated with NH₃ gas (25 mL) for 96 h at rt to afford the corresponding primary amine (608 mg, crude product). A solution of the crude primary amine in THF (43 mL) was then treated with *i*-Pr₂N₂Et (465 μ L, 2.67 mmol) and BrCH₂CN (178 μ L, 2.67 mmol) for 18 h at rt to afford the corresponding secondary amine (707 mg, crude product) as a pale yellow oil. A solution of the crude secondary amine in THF (42 mL) was then treated with *N*-formylbenzotriazole (448 mg, 3.05 mmol) for 18 h at rt to afford, after the usual purification using silica gel saturated with Et₃N (40 to 100% EtOAc in hexanes), an inseparable mixture of *E*/*Z* isomers of 94 (504 mg, 65% over 3 steps) each in a 8:1 rotamer ratio, as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.15 (s) and 8.02 (s) (1H), 6.21 (d, J = 12.5 Hz), 6.09 (d, J = 6.0 Hz), and 6.03 (d, J = 6.0 Hz) (1H), 5.98–5.83 (m, 1H), 5.81–5.58 (m, 1H), 5.37–5.18 (m, 2H), 5.13–4.96 (m, 2H), 4.74–4.69 (m), 4.62–4.57 (m), 4.51 (dd, J = 12.5, 10.5 Hz), 4.36 (d, J = 17.5 Hz), 4.30–4.18 (m), 4.17–4.12 (m), 4.09 (d, J = 17.5 Hz), and 3.98–3.90 (m) (5H), 3.68–3.53 (m, 2H), 3.43 (dd, J = 14.5, 5.0 Hz), 3.37 (d, J = 6.0 Hz), 3.28 (dd, J = 14.5, 8.5 Hz), and 3.18 (dd, J = 14.5, 9.5 Hz) (2H), 2.73–2.49 (m) and 2.22–1.90 (m) (3H), 1.86–1.13 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) only the major rotamer

of *E* and *Z* isomers reported δ (ppm) 163.5 (d), 163.4 (d), 148.2 (d), 146.8 (d), 135.8 (d), 135.6 (d), 133.9 (d), 133.6 (d), 118.2 (t), 118.1 (t), 118.0 (t), 118.0 (t), 114.9 (s), 114.8 (s), 107.8 (d), 104.2 (d), 72.8 (t), 70.3 (t), 62.3 (t), 62.2 (t), 48.7 (t), 48.5 (t), 40.0 (d), 39.8 (d), 38.2 (d), 33.7 (d), 33.0 (t), 32.8 (t), 30.2 (t), 30.1 (t), 30.0 (t), 29.7 (t), 28.2 (t), 27.2 (t); IR (film) ν (cm⁻¹) 3647–3156, 3080, 2933, 2871, 1672, 1431, 1285; MS (ESI) m/z (rel %) 345 [MK⁺] (2), 329 [MNa⁺] (100), 290 (18); HRMS (ESI) calcd for C₁₇H₂₆N₂O₃Na [MNa⁺] 329.1836, found 329.1836.

(Z)-rel-(6S,7S)-Methyl 6-(2-(allyloxy)vinyl)-7-((N-(cyanomethyl)formamido)methyl)deca-2,9-dienoate (95). Following the procedure used to prepare **83**, a solution **94** (197 mg, 0.643 mmol) in DCM (3.0 mL) was added to a solution of oxalyl chloride (62 μ L, 0.71 mmol) and DMSO (92 μ L, 1.3 mmol) in DCM (10 mL), and the mixture was then treated with Et₃N (450 μ L, 3.22 mmol) to afford the corresponding aldehyde (196 mg of crude material). A solution of crude aldehyde in THF (3.0 mL) was then added to a solution of KHMDS (0.5 M in toluene, 1.42 mL, 0.707 mmol), methyl bis(2,2,2-trifluoroethyl)phosphonoacetate (215 mg, 0.643 mmol), and 18-crown-6 ether (425 mg, 1.61 mmol) in THF (10 mL) to afford, after the usual workup (Et₂O) and purification using silica gel saturated with Et₃N (20 to 60% EtOAc in hexanes), an inseparable mixture of *E/Z* isomers and rotamers of **95** (176 mg, 76% over 2 steps) as a pale yellow oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.12 (s) and 7.99 (s) (1H), 6.23–6.12 (m), 6.18 (d, *J* = 12.5 Hz), and 6.08 (d, *J* = 6.5 Hz) (2H), 5.95–5.81 (m, 1H), 5.76 (d, *J* = 11.5 Hz) and 5.73–5.55 (m) (2H), 5.29 (dd, *J* = 17.5, 1.5 Hz), 5.21 (dd, *J* = 10.5, 1.0 Hz), and 5.09–4.96 (m) (4H), 4.57 (d, *J* = 6.5 Hz) and 4.49 (dd, *J* = 12.5, 10.0 Hz) (1H), 4.37 (d, *J* = 17.5 Hz), 4.26 (s), and 4.13 (d, *J* = 17.5 Hz) (2H), 4.22–4.16 (m, 2H), 3.66 (s, 3H), 3.52–3.21 (m), 3.41 (dd, *J* = 14.5, 4.5 Hz), and 3.14 (dd, *J* = 14.5, 10.0 Hz) (2H), 2.75–2.46 (m, 2H), 2.12–1.92 (m, 3H), 1.85–1.73 (m, 1H), 1.62–1.52 (m, 1H), 1.47–1.30 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) *E*-isomer (major rotamer): 166.5 (s), 162.7 (d), 149.5 (d), 147.8 (d), 135.1 (d), 133.1 (d), 119.7 (d), 117.8 (t), 117.5 (t), 114.6 (s), 103.3 (d), 70.2 (t), 51.0 (q), 48.6 (t), 39.1 (d), 38.3 (d), 33.3 (t), 31.8 (t), 30.3 (t), 26.8 (t); *Z*-isomer (major rotamer) and *E*-isomer (minor rotamer): 166.6 (s), 162.8 (d), 162.4 (d), 150.0 (d), 149.9 (d), 147.5 (d), 146.4 (d), 136.0 (d), 135.2 (d), 133.5 (d), 133.2 (d), 119.5 (d), 119.4 (d), 117.6 (t), 117.4 (t), 117.0 (t), 114.8 (s), 106.8 (d), 103.4 (d), 72.7 (t), 69.9 (t), 50.9 (q), 48.6 (t), 43.7 (t), 39.4 (d), 38.7 (d), 36.0 (t), 34.2 (d), 33.8 (t), 33.1 (t), 31.7 (t), 31.0 (t), 30.0 (t), 26.9 (t), 26.8 (t); IR (film) ν (cm⁻¹) 3083, 2982, 2927, 2876, 1719, 1680, 1644, 1437, 1407, 1203, 1175; MS (ESI) m/z (rel %) 399 [MK⁺] (9), 383 [MNa⁺] (100); HRMS (ESI) calcd for C₂₀H₂₈N₂O₄Na [MNa⁺] 383.1941, found 383.1941.

(Z)-Methyl 5-(rel-(1S,2S)-2-((N-(Cyanomethyl)formamido)methyl)-7-formylcyclohept-4-en-1-yl)pent-2-enoate (96). A solution of **95** (359 mg, 1.00 mmol) in toluene (20 mL) was heated at 155 °C in a sealed tube for 96 h. The solution was concentrated under reduced pressure to afford the corresponding diene (359 mg of crude product). The crude diene (359 mg) was dissolved in DCM (165 mL), and second-generation Grubbs' catalyst (42 mg, 5 mol %) was added. The solution was stirred for 3 h at rt and then concentrated under reduced pressure. The usual purification (40 to 80% EtOAc in hexanes) afforded an inseparable mixture of diastereomers and rotamers of **96** (213 mg, 64%) as a brown oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 9.74 (s), 9.73 (s), 9.65 (s), and 9.64 (s) (1H), 8.22 (s), 8.16 (s), 8.15 (s), and 8.07 (s) (1H), 6.21 (dt, *J* = 11.5, 8.0 Hz, 1H), 5.88–5.62 (m, 3H), 4.64 (d, *J* = 17.5 Hz), 4.49 (d, *J* = 17.5 Hz), 4.41 (d, *J* = 18.0 Hz), 4.32 (s), 4.27 (s), 4.26 (d, *J* = 17.5 Hz), and 4.18 (d, *J* = 17.5 Hz) (2H), 3.90 (dd, *J* = 14.5, 10.5 Hz), 3.47 (dd, *J* = 14.5, 6.0 Hz), 3.43–3.25 (m), and 3.01 (dd, *J* = 14.5, 5.0 Hz) (2H), 3.70 (s), 3.69 (s), and 3.67 (s) (3H), 2.79–1.77 (m, 9H), 1.71–1.40 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) only the major rotamer of each diastereomer reported δ (ppm) 205.2 (d), 204.0 (d), 167.2 (s), 167.1 (s), 163.5 (d), 163.1 (d), 149.0 (d), 148.9 (d), 131.0 (d), 129.8 (d), 129.0 (d), 128.6 (d), 121.0 (d), 120.7 (d), 115.0 (s), 114.9 (s), 55.6 (d), 51.1 (t), 51.1 (d), 51.0 (q), 50.8 (q), 49.3 (t), 40.3 (d), 39.1 (d), 36.5 (d), 33.1 (d), 30.2 (t), 29.4 (t), 28.0 (t), 27.4 (t), 27.1 (t), 25.6

(t), 25.2 (t), 24.7 (t), 24.3 (t), 24.0 (t); IR (film) ν (cm⁻¹) 3022, 2948, 2934, 1718, 1678, 1437, 1406, 1202, 1177; MS (ESI) m/z (rel %) 371 [MK⁺] (29), 355 [MNa⁺] (100), 333 [MH⁺] (2); HRMS (ESI) calcd for C₁₈H₂₄N₂O₄Na [MNa⁺] 355.1628, found 355.1630.

Methyl rel-(1R,2S,3R,6S,11S,12S,15S)-4-Aza-3-cyano-11-formyltetracyclo[9.3.1.0^{4,15}.0^{6,12}]pentadec-8-ene-2-carboxylate (98 α -CN) and Methyl rel-(1R,2S,3S,6S,11S,12S,15S)-4-Aza-3-cyano-11-formyltetracyclo[9.3.1.0^{4,15}.0^{6,12}]pentadec-8-ene-2-carboxylate (98 β -CN). Tf₂O (84 μ L, 0.50 mmol) was added to a solution of **92** (178 mg, 0.399 mmol) and DTBMP (246 mg, 1.20 mmol) in DCM (40 mL) at rt. After 15 min at rt, an additional portion of Tf₂O (84 μ L, 0.50 mmol) was added and another additional portion (35 μ L, 0.21 mmol) after 10 min. Progression of the Vilsmeier–Haack cyclization was monitored by TLC. *i*-Pr₂NEt (0.56 mL, 3.2 mmol) was then added at rt, and the mixture was stirred for 1 h. Saturated aqueous NaHCO₃ was added. The usual workup (EtOAc) and purification (2 to 10% MeCN in toluene) afforded two separable diastereomers **98 α -CN** (54.5 mg) and **98 β -CN** (52.5 mg) (86% global yield) as pale yellow oils: **98 α -CN**: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 9.39 (s, 1H), 5.70–5.59 (m, 2H), 4.31 (bs, 1H), 3.75 (s, 3H), 3.41 (dd, *J* = 14.0, 8.5 Hz, 1H), 3.33 (dd, *J* = 9.0, 6.0 Hz, 1H), 3.18 (dd, *J* = 14.0, 5.5 Hz, 1H), 3.13 (bs, 1H), 2.81–2.74 (m, 1H), 2.55–2.47 (m, 1H), 2.35–2.19 (m, 4H), 1.72–1.45 (m, 5H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 201.2 (d), 169.7 (s), 128.9 (d), 124.9 (d), 117.3 (s), 61.6 (d), 54.7 (d), 52.2 (q), 52.2 (d), 50.3 (s), 49.7 (t), 37.5 (d), 36.4 (t), 34.6 (d), 34.0 (d), 32.6 (t), 28.3 (t), 19.1 (t); IR (film) ν (cm⁻¹) 3016, 2956, 2930, 2889, 1722, 1439, 1203, 1177; MS (ESI) m/z (rel %) 315 [MH⁺] (100), 288 [M⁺ – CN] (13), 198 (6); HRMS (ESI) calcd for C₁₈H₂₃N₂O₃ [MH⁺] 315.1709, found 315.1704. **98 β -CN**: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 9.39 (s, 1H), 5.65–5.57 (m, 2H), 4.27 (d, *J* = 8.0 Hz, 1H), 3.74 (s, 3H), 3.42 (bs, 1H), 3.35 (dd, *J* = 8.0, 6.0 Hz, 1H), 3.29 (dd, *J* = 14.0, 6.5 Hz, 1H), 2.94 (dd, *J* = 14.0, 9.0 Hz, 1H), 2.75–2.63 (m, 2H), 2.31–2.11 (m, 4H), 1.64–1.52 (m, 2H), 1.50–1.35 (m, 2H), 1.15–1.03 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 201.1 (d), 170.5 (s), 128.8 (d), 124.4 (d), 120.9 (s), 61.2 (d), 57.8 (d), 55.4 (d), 53.9 (t), 52.5 (q), 50.3 (s), 38.5 (d), 36.3 (t), 34.2 (d), 33.2 (d), 31.7 (t), 28.1 (t), 18.6 (t); IR (film) ν (cm⁻¹) 3016, 2928, 2885, 1725, 1438, 1241, 1204, 1170; MS (ESI) m/z (rel %) 315 [MH⁺] (100), 288 [M⁺ – CN] (11), 198 (5); HRMS (ESI) calcd for C₁₈H₂₃N₂O₃ [MH⁺] 315.1709, found 315.1714.

N-(rel-(2S,3S)-(6Z)-2-Allyl-3-(2-(allyloxy)vinyl)oct-6-en-1-yl)-N-(cyanomethyl)formamide (99). Following the procedure used to prepare **83**, a solution of **94** (100 mg, 0.326 mmol) in DCM (2.0 mL) was added to a solution of oxalyl chloride (32 μ L, 0.36 mmol) and DMSO (46 μ L, 0.65 mmol) in DCM (5 mL), and the mixture was then treated with Et₃N (227 μ L, 1.63 mmol) to afford the corresponding aldehyde (107 mg of crude material). Ph₃PtBr (145 mg, 0.390 mmol) was added to a solution of *t*-BuOK (40 mg, 0.36 mmol) in THF (4.0 mL) at 0 °C. After 20 min at rt, a solution of aldehyde (107 mg of crude material) in THF (2.5 mL) was added, and the mixture was allowed to warm up to rt and stirred 18 h. Water was added, and solvent was removed under reduced pressure. Saturated aqueous NaHCO₃ was added. The usual workup (EtOAc) and purification using silica gel saturated with Et₃N (30% EtOAc in hexanes) afforded a mixture of *E/Z* isomers (for the allyl enol ether) and rotamers of **99** (27 mg, 76% over 2 steps) as a pale yellow oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.13 (s) and 8.01 (s) (1H), 6.19 (d, *J* = 12.5 Hz), 6.18 (d, *J* = 12.5 Hz), 6.09 (d, *J* = 6.5 Hz), and 6.06 (d, *J* = 5.5 Hz) (1H), 5.98–5.83 (m, 1H), 5.81–5.62 (m, 1H), 5.50–5.38 (m, 1H), 5.37–5.20 (m, 3H), 5.10–5.00 (m, 2H), 4.55 (dd, *J* = 12.5, 10.0 Hz), 4.51 (dd, *J* = 12.5, 10.0 Hz), and 4.14 (dd, *J* = 6.5, 3.5 Hz) (1H), 4.35 (d, *J* = 17.5 Hz), 4.28–4.17 (m), 4.09 (d, *J* = 17.5 Hz) (4H), 3.41 (dd, *J* = 14.5, 5.0 Hz), 3.36 (dd, *J* = 14.5, 6.0 Hz), 3.28 (dd, *J* = 14.5, 8.0 Hz), and 3.18 (dd, *J* = 14.5, 9.5 Hz) (2H), 2.62–2.53 (m) and 2.17–1.89 (m) (5H), 1.80–1.56 (m, 4H), 1.50–1.40 (m, 1H), 1.38–1.20 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 162.7 (d), 162.7 (d), 162.3 (d), 162.2 (d), 147.8 (d), 147.5 (d), 146.3 (d), 146.0 (d), 136.5 (d), 136.1 (d), 135.4 (d), 135.2 (d), 133.7 (d), 133.6 (d), 133.3 (d), 133.2 (d), 130.3 (d), 130.0 (d), 129.9 (d), 129.6 (d), 124.6 (d), 124.4 (d), 124.2 (d), 124.0 (d), 117.9 (t), 117.7 (t), 117.0 (t), 117.0 (t),

117.6 (t), 117.1 (t), 116.7 (t), 114.6 (s), 114.5 (s), 108.3 (d), 107.8 (d), 104.1 (d), 72.8 (t), 72.7 (t), 70.4 (t), 70.1 (t), 48.9 (t), 48.7 (t), 44.2 (t), 43.4 (t), 40.2 (d), 40.1 (d), 40.0 (d), 39.7 (d), 38.7 (d), 38.1 (d), 38.0 (d), 36.2 (t), 35.6 (t), 34.1 (t), 34.0 (t), 33.9 (t), 33.5 (t), 33.3 (t), 33.0 (t), 32.3 (t), 31.4 (t), 30.9 (t), 30.3 (t), 29.9 (t), 25.0 (t), 24.8 (t), 24.7 (t), 24.6 (t), 17.9 (q), 12.9 (q), 12.9 (q), 12.7 (q); IR (film) ν (cm⁻¹) 3077, 3017, 2932, 2867, 1679, 1425, 1405, 1161; MS (ESI) m/z (rel %) 339 [MNa⁺] (100); HRMS (ESI) calcd for C₁₉H₂₈N₂O₂Na [MNa⁺] 339.2043, found 339.2049.

***N*-(*rel*-(2*S*,3*S*)-(Z)-2-Allyl-3-(1-oxopent-4-en-2-yl)oct-6-en-1-yl)-*N*-(cyanomethyl)formamide (100).** A solution of **99** (27 mg, 85 μ mol) in toluene (3.0 mL) was heated at 155 °C in a sealed tube for 144 h. The solution was concentrated under reduced pressure. The usual purification using silica gel saturated with Et₃N (20 to 40% EtOAc in hexanes) afforded an inseparable mixture of diastereomers and rotamers of **100** (24 mg, 89%) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 9.71 (d, J = 2.0 Hz), 9.78 (d, J = 2.0 Hz), and 9.67 (d, J = 2.0 Hz) (1H), 8.15 (s), 8.14 (s), 8.11 (s), and 8.02 (s) (1H), 5.80–5.61 (m, 2H), 5.57–5.42 (m, 1H), 5.39–5.25 (m, 1H), 5.18–4.99 (m, 4H), 4.43–4.08 (m), 4.36 (d, J = 17.5 Hz), 4.32 (d, J = 16.0 Hz), 4.18 (d, J = 17.5 Hz), and 4.13 (d, J = 17.5 Hz) (2H), 3.65–3.49 (m) and 3.36–3.19 (m) (2H), 2.60–2.40 (m, 2H), 2.38–1.79 (m, 7H), 1.68–1.32 (m, 2H), 1.59 (d, J = 6.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 208.1 (d), 205.1 (d), 204.8 (d), 204.0 (d), 162.6 (d), 162.5 (d), 135.9 (d), 135.3 (d), 135.1 (d), 134.8 (d), 134.7 (d), 132.1 (d), 129.4 (d), 129.3 (d), 128.8 (d), 128.8 (d), 128.5 (d), 125.1 (d), 124.8 (d), 119.7 (t), 118.2 (t), 118.1 (t), 117.9 (t), 117.7 (t), 117.6 (t), 117.5 (t), 117.3 (t), 114.5 (s), 114.5 (s), 114.4 (s), 52.5 (d), 52.4 (d), 52.1 (d), 50.5 (t), 49.2 (t), 49.2 (t), 45.7 (d), 44.5 (t), 40.1 (d), 38.0 (d), 37.5 (d), 37.4 (d), 37.3 (d), 36.9 (d), 36.6 (d), 36.3 (d), 36.0 (t), 36.0 (t), 34.7 (t) 34.0 (t), 33.2 (t), 33.1 (t), 33.0 (t), 32.9 (t), 31.6 (t), 31.2 (t), 31.2 (t), 31.1 (t), 30.2 (t), 30.2 (t), 27.2 (t), 27.1 (t), 26.7 (t), 26.6 (t), 26.3 (t), 25.8 (t), 25.5 (t), 25.4 (t), 25.3 (t), 24.7 (t), 13.4 (q), 13.0 (q), 12.9 (q), 12.8 (q); IR (film) ν (cm⁻¹) 3077, 3012, 2927, 2862, 1724, 1672, 1430, 1395, 1180, 916; MS (ESI) m/z (rel %) 371 [MNa⁺ + MeOH] (32), 355 [MK⁺] (30), 339 [MNa⁺] (100); HRMS (ESI) calcd for C₁₉H₂₈N₂O₂Na [MNa⁺] 339.2043, found 339.2046.

***N*-(Cyanomethyl)-*N*-(*rel*-(1*S*,7*S*)-6-formyl-7-(Z)-pent-3-en-1-yl)cyclohept-3-en-1-yl)methylformamide (101).** First-generation Grubbs' catalyst (5.9 mg, 5 mol %) was added to a solution of **100** (45.2 mg, 0.143 mmol) in DCM (14.5 mL). The solution was stirred for 6 h at rt with N₂ bubbling; then another portion of first-generation Grubbs' catalyst (5.9 mg, 5 mol %) was added. The solution was stirred at rt for 18 h, and water was finally added. The usual workup (DCM) and purification (0 to 40% EtOAc in hexanes) afforded an inseparable mixture of diastereomers and rotamers of **101** (36.0 mg, 88%) as a pale yellow oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 9.73 (s) and 9.65 (s) (1H), 8.22 (s), 8.17 (s), 8.06 (s), and 8.02 (s) (1H), 5.86–5.57 (m), 5.54–5.41 (m), 5.37–5.23 (m), and 5.14–4.96 (m) (4H), 4.66–4.02 (m), 4.62 (d, J = 17.5 Hz), 4.49 (d, J = 17.5 Hz), 4.22 (d, J = 17.5 Hz), and 4.12 (d, J = 17.5 Hz) (2H), 3.49–3.05 (m, 2H), 2.66–1.72 (m, 10H), 1.67–1.13 (m) and 1.08–0.83 (m) (4H); ¹³C NMR (75.5 MHz, CDCl₃) only the major rotamer of each diastereomer reported δ (ppm) 204.6, 203.3, 162.4, 162.3, 130.9, 129.2, 128.9, 128.8, 128.4, 127.9, 125.4, 114.6, 114.5, 56.0, 51.8, 51.2, 50.0, 41.2, 38.2, 35.9, 33.6, 30.6, 29.6, 28.6, 27.3, 25.5, 25.2, 24.9, 24.2, 24.0, 23.9, 12.8; MS (ESI) m/z (rel %) 343 [MNa⁺ + MeOH] (19), 311 [MNa⁺] (100), 297 (41); HRMS (ESI) calcd for C₁₇H₂₄N₂O₂Na [MNa⁺] 311.1730, found 311.1734.

***N*-(*rel*-(1*S*,7*S*)-6-(((*tert*-Butyldimethylsilyloxy)methylene)-7-(Z)-pent-3-en-1-yl)cyclohept-3-en-1-yl)methyl)-*N*-(cyanomethyl)formamide (102).** Following the procedure used to prepare **40**, a solution of **101** (34 mg, 0.12 mmol) in DCM (2.5 mL) was treated with TBDMSOTf (54 μ L, 0.24 mmol) and *i*-Pr₂NEt (62 μ L, 0.35 mmol) for 18 h at rt to afford, after the usual purification using silica gel saturated with Et₃N (0 to 40% EtOAc in hexanes), one geometrical isomer (as a mixture of rotamers) of **102** (22.5 mg, 47%) of unidentified stereochemistry as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.18 (s) and 8.01 (s) (1H), 6.07 (s, 1H), 5.85–5.70

(m, 1H), 5.61–5.27 (m, 3H), 5.05–4.94 (m), 4.33 (d, J = 17.5 Hz), and 4.17 (d, J = 17.5 Hz) (2H), 3.34–3.20 (m, 2H), 3.13 (dd, J = 17.0, 6.5 Hz, 1H), 2.78–2.59 (m, 1H), 2.18–1.79 (m, 6H), 1.73–1.51 (m, 1H), 1.58 (d, J = 7.0 Hz, 3H), 1.34–1.18 (m, 1H), 0.92 (s, 9H), 0.12 (s, 6H); ¹³C NMR (75.5 MHz, CDCl₃) only the major rotamer reported δ (ppm) 162.5, 135.1, 130.2, 129.8, 126.4, 124.7, 119.9, 114.4, 50.1, 43.5, 39.6, 30.1, 28.7, 26.0, 25.6, 25.3, 24.5, 18.3, 12.9, –5.3; MS (ESI) m/z (rel %) 457 [MNa⁺ + O₂] (45), 425 [MNa⁺] (100), 411 (18); HRMS (ESI) calcd for C₂₃H₃₈N₂O₂SiNa [MNa⁺] 425.2595, found 425.2605.

***rel*-(1*S*,6*S*,10*S*)-8-(Cyanomethyl)-1-formyl-10-((Z)-pent-3-en-1-yl)-8-azabicyclo[4.3.1]deca-3,8-dien-8-ium Trifluoromethanesulfonate (103).** Tf₂O (3.0 μ L, 19 μ mol) was added to a solution of **102** (5.0 mg, 12 μ mol) and DTBMP (7.6 mg, 37 μ mol) in DCE (0.7 mL) at rt. After 10 min, an additional portion of Tf₂O (1.0 μ L, 0.6 μ mol) was added. ¹H NMR analysis showed the formation of the iminium ion **103**: ¹H NMR (300 MHz, CD₂Cl₂) characteristic signals δ (ppm) 9.69 (s, 1H), 9.39 (s, 1H), 6.16–6.06 (m, 1H), 5.82–5.66 (m, 1H), 5.60–5.50 (m, 1H), 5.42 (d, J = 17.5 Hz, 1H), 5.34–5.29 (m, 1H), 5.22 (d, J = 17.5 Hz, 1H), 4.13 (dd, J = 17.0, 4.5 Hz, 1H), 3.82 (d, J = 17.0 Hz, 1H), 2.92–2.58 (m), 2.40–1.89 (m), and 1.67–0.83 (m) (13H).

Methyl *rel*-(1*R*,6*S*,11*S*,12*S*,15*S*)-4-Aza-11-(*E*)-3-(*tert*-butoxy)-3-oxoprop-1-enyl)-3-cyanotetra-cyclo[9.3.1.0^{4,15}.0^{6,12}]penta-dec-8-ene-2-carboxylate (105). *t*-BuOK (5.2 mg, 44 μ mol) was added to a solution of *tert*-butyl diethylphosphonoacetate (14.0 mg, 55.4 μ mol) in THF (1.0 mL) at 0 °C. The mixture was stirred for 30 min at 0 °C; then a solution of **98 α / β -CN** (11.6 mg, 36.9 μ mol) in THF (1.0 mL) was added. The reaction mixture was stirred for 2 h at 0 °C. Saturated aqueous NaHCO₃ was added at 0 °C. The usual workup (EtOAc) and purification (5 to 30% EtOAc in hexanes) gave three separable diastereomers **105** (11.7 mg, 77%) as a pale yellow oil: Diastereoisomer 1: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 6.86 (d, J = 16.5 Hz, 1H), 5.67 (d, J = 16.5 Hz, 1H), 5.61–5.55 (m, 2H), 4.30 (d, J = 8.0 Hz, 1H), 3.74 (s, 3H), 3.37 (bs, 1H), 3.32 (d, J = 6.0 Hz, 1H), 3.28 (t, J = 6.0 Hz, 1H), 2.93 (dd, J = 14.0, 9.5 Hz, 1H), 2.81 (d, J = 15.5 Hz, 1H), 2.62–2.50 (m, 1H), 2.31–1.95 (m, 5H), 1.77–1.63 (m, 1H), 1.58–1.32 (m, 2H), 1.50 (s, 9H), 1.14–0.98 (m, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 170.4 (s), 166.1 (s), 154.3 (d), 128.6 (d), 124.8 (d), 121.1 (s), 120.3 (d), 80.6 (s), 64.4 (d), 58.1 (d), 55.2 (d), 54.3 (t), 52.4 (q), 41.0 (s), 38.5 (d), 37.8 (t), 36.4 (t), 36.3 (d), 34.1 (d), 28.1 (q), 27.7 (t), 18.7 (t); IR (film) ν (cm⁻¹) 3023, 2957, 2922, 2876, 1735, 1709, 1644, 1206, 1151; MS (ESI) m/z (rel %): 435 [MNa⁺] (41), 413 [MH⁺] (80), 408 [MNa⁺ – HCN] (100); HRMS (ESI) calcd for C₂₄H₃₃N₂O₄ [MH⁺] 413.2435, found 413.2444. Diastereoisomer 2: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 6.84 (d, J = 16.5 Hz, 1H), 5.82–5.68 (m, 2H), 5.67 (d, J = 16.5 Hz, 1H), 4.12 (d, J = 7.5 Hz, 1H), 3.75 (s, 3H), 3.08–3.00 (m, 3H), 2.91 (d, J = 5.0 Hz, 1H), 2.69–2.58 (m, 1H), 2.58 (dd, J = 16.0, 6.5 Hz, 1H), 2.36–2.26 (m, 2H), 2.16–1.83 (m, 5H), 1.55–1.41 (m, 1H), 1.49 (s, 9H), 1.38–1.24 (m, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 173.1 (s), 166.2 (s), 154.5 (d), 128.5 (d), 128.1 (d), 120.5 (d), 117.7 (s), 80.6 (s), 65.3 (d), 57.7 (d), 57.7 (d), 52.6 (q), 52.3 (t), 40.5 (d), 40.0 (t), 38.6 (s), 37.3 (d), 35.5 (t), 34.9 (d), 28.4 (t), 28.2 (t), 28.1 (q); IR (film) ν (cm⁻¹) 3023, 2959, 2921, 2876, 1739, 1709, 1644, 1209, 1147; MS (ESI) m/z (rel %): 435 [MNa⁺] (100), 413 [MH⁺] (69); HRMS (ESI) calcd for C₂₄H₃₃N₂O₄Na [MNa⁺] 435.2254, found 435.2269. Diastereoisomer 3: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 6.87 (d, J = 16.5 Hz, 1H), 5.65–5.59 (m, 2H), 5.64 (d, J = 16.5 Hz, 1H), 4.35 (d, J = 9.5 Hz, 1H), 3.75 (s, 3H), 3.40 (dd, J = 14.5, 8.5 Hz, 1H), 3.27 (dd, J = 9.0, 6.0 Hz, 1H), 3.15 (dd, J = 14.5, 6.5 Hz, 1H), 3.09–3.02 (m, 1H), 2.73–2.53 (m, 2H), 2.33–2.06 (m, 5H), 1.98 (bs, 1H), 1.78–1.56 (m, 2H), 1.48 (s, 9H), 1.56–1.41 (m, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 169.7 (s), 166.2 (s), 154.9 (d), 128.7 (d), 125.3 (d), 120.2 (d), 117.6 (s), 80.6 (s), 64.8 (d), 54.8 (d), 52.4 (d), 52.1 (q), 49.6 (t), 41.2 (s), 39.0 (t), 37.7 (d), 37.2 (d), 36.4 (t), 34.6 (d), 28.1 (q), 27.9 (t), 19.0 (t); IR (film) ν (cm⁻¹) 3016, 2943, 2931, 2884, 1744, 1709, 1641, 1215, 1152; MS (ESI) m/z (rel %): 435 [MNa⁺] (25), 413 [MH⁺] (100), 408 [MNa⁺ – HCN] (35); HRMS (ESI) calcd for C₂₄H₃₃N₂O₄ [MH⁺] 413.2435, found 413.2447.

Methyl *rel*-(1*R*,6*S*,11*S*,12*S*,15*S*)-4-Aza-11-((*E*)-3-(*tert*-butoxy)-3-oxoprop-1-enyl)tetracyclo[9.3.1.0^{4,15}.0^{6,12}]pentadeca-2,8-diene-2-carboxylate (1016). A solution of **105** (19.2 mg, 46.5 μ mol) in toluene (2.0 mL) was added to a solution of NaH (60% in mineral oil, 93 mg, 2.3 mmol) in toluene (3.0 mL) at 0 °C. Then, the mixture was refluxed for 12 h. Water was added at 0 °C. The usual workup (EtOAc, washed with brine) and purification (0 to 30% EtOAc in hexanes) afforded **105** (14.9 mg, 83%) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.11 (s, 1H), 7.09 (d, *J* = 16.0 Hz, 1H), 5.76 (d, *J* = 16.0 Hz, 1H), 5.66–5.47 (m, 2H), 3.98 (d, *J* = 10.0 Hz, 1H), 3.65 (s, 3H), 3.58 (dd, *J* = 14.0, 10.5 Hz, 1H), 3.33 (dd, *J* = 14.0, 9.0 Hz, 1H), 3.11 (t, *J* = 7.5 Hz, 1H), 2.63 (d, *J* = 16.5 Hz, 1H), 2.44 (dt, *J* = 18.5, 6.0 Hz, 1H), 2.35–2.19 (m, 2H), 2.12–1.91 (m, 3H), 1.72–1.56 (m, 1H), 1.49 (s, 9H), 1.43–1.23 (m, 1H), 1.13 (dd, *J* = 14.5, 3.0 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm) 166.5 (s), 166.4 (s), 154.8 (d), 153.0 (d), 131.2 (d), 122.9 (d), 118.9 (d), 104.6 (s), 80.4 (s), 65.4 (d), 50.4 (q), 50.0 (t), 42.0 (s), 40.3 (d), 40.0 (d), 38.5 (t), 34.7 (t), 34.3 (d), 28.2 (q), 26.1 (t), 23.7 (t); MS (ESI) *m/z* (rel %): 408 [MNa⁺] (100), 386 [MH⁺] (20); HRMS (ESI) calcd for C₂₃H₃₁NO₄Na [MNa⁺] 408.2145, found 408.2161.

***tert*-Butyl *rel*-(1*R*,2*S*,6*S*,11*S*,12*S*,15*S*)-4-Aza-2-(hydroxymethyl)tetracyclo[9.3.1.0^{4,15}.0^{6,12}]pentadecane-11-propanoate (107).** A solution of **106** (12.4 mg, 32.1 μ mol) and Pd/C (10%, 3.4 mg, 10 mol %) in MeOH (1.5 mL) was stirred under a hydrogen atmosphere (50 psi) for 36 h. The mixture was filtered on Celite and concentrated under reduced pressure to afford the corresponding saturated compound (12.6 mg, quantitative) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ (ppm) 3.67 (s, 3H), 3.48–3.36 (m, 1H), 3.21 (dd, *J* = 11.0, 8.0 Hz, 2H), 3.00 (dd, *J* = 15.0, 8.0 Hz, 1H), 2.84 (t, *J* = 12.5 Hz, 1H), 2.72 (bs, 1H), 2.66–2.58 (m, 1H), 2.53–2.40 (m, 1H), 2.29–2.14 (m, 3H), 2.00–1.53 (m, 10H), 1.51–1.33 (m, 3H), 1.45 (s, 9H), 1.30–1.17 (m, 1H); MS (ESI) *m/z* (rel %): 392 [MH⁺] (100); HRMS (ESI) calcd for C₂₃H₃₈NO₄ [MH⁺] 392.2795, found 392.2808. The latter (12.6 mg, 32.1 μ mol) was dissolved in THF, (2.0 mL) and a solution of LiBH₄ (2.0 M in THF, 32 μ L, 64 μ mol) was added at 0 °C. After 30 min, an additional portion of LiBH₄ (2.0 M in THF, 32 μ L, 64 μ mol) was added. The mixture was stirred for 14 h at rt; then water was added. Solvent was removed under reduced pressure, and saturated aqueous NaHCO₃ was added. The usual workup (EtOAc, Na₂SO₄) and purification (20 to 50% EtOAc in hexanes) gave **107** (4.9 mg, 42%, 49% brsm) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 3.68–3.58 (m, 2H), 3.55 (dd, *J* = 10.5, 6.5 Hz, 1H), 3.28 (dd, *J* = 15.0, 11.0 Hz, 1H), 3.20 (d, *J* = 3.5 Hz, 1H), 3.12 (t, *J* = 11.5 Hz, 1H), 2.88 (dd, *J* = 15.0, 9.5 Hz, 1H), 2.72–2.48 (m, 3H), 2.21 (dd, *J* = 9.0, 8.0 Hz, 2H), 2.13–2.04 (m, 1H), 1.86–1.64 (m, 7H), 1.60–1.40 (m, 8H), 1.44 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 173.7 (s), 80.5 (s), 72.8 (d), 67.8 (t), 59.7 (t), 58.4 (t), 42.6 (d), 37.0 (d), 36.2 (s), 35.1 (t), 34.1 (d), 33.0 (d), 32.6 (t), 32.2 (t), 28.8 (t), 27.8 (q), 25.2 (t), 24.0 (t), 23.9 (t), 15.2 (t); IR (film) ν (cm⁻¹) 3448, 2975, 2932, 2878, 1725, 1478, 1455, 1152; MS (ESI) *m/z* (rel %): 364 [MH⁺] (100); HRMS (ESI) calcd for C₂₂H₃₈NO₃ [MH⁺] 364.2846, found 364.2862.

■ ASSOCIATED CONTENT

■ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b01835.

Copies of ¹H and ¹³C NMR spectra for all new compounds, and copies of 2D NMR spectra for compounds **Z-91**, **98 α -CN**, **98 β -CN**, and **107** (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: Guillaume.Belanger@USherbrooke.ca.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research was supported by the Natural Science and Engineering Research Council (NSERC) of Canada, the Canadian Fund for Innovation (CFI), and the Université de Sherbrooke. NSERC masters and doctoral fellowships, Fonds de Recherche du Québec en Nature et Technologies (FRQNT) masters and doctoral fellowships, and Center in Green Chemistry and Catalysis (CGCC) scholarship to J.B. are also gratefully acknowledged.

■ REFERENCES

- (1) (a) Kang, B.; Jakubec, P.; Dixon, D. J. *Nat. Prod. Rep.* **2014**, *31*, 550–562 and references cited therein. (b) Yang, T.-Q.; Di, Y.-T.; He, H.-P.; Zhang, Q.; Zhang, Y.; Hao, X.-J. *Helv. Chim. Acta* **2011**, *94*, 397–403. (c) Dong, M.; Zhang, M.-L.; Shi, Q.-W.; Gu, Y.-C.; Kiyota, H. *Curr. Org. Chem.* **2009**, *13*, 646–682.
- (2) For a selection of *Daphniphyllum* alkaloids total syntheses, see: (a) Chattopadhyay, A. K.; Ly, V. L.; Jakkepally, S.; Berger, G.; Hanessian, S. *Angew. Chem., Int. Ed.* **2016**, *55*, 2577–2581. (b) Yamada, R.; Adachi, Y.; Yokoshima, S.; Fukuyama, T. *Angew. Chem., Int. Ed.* **2016**, *55*, 6067–6070. (c) Shvartsbart, A.; Smith, A. B., III *J. Am. Chem. Soc.* **2014**, *136*, 870–873. (d) Heathcock, C. H.; Kath, J. C.; Ruggeri, R. B. *J. Org. Chem.* **1995**, *60*, 1120–1130. (e) Heathcock, C. H.; Stafford, J. A.; Clark, D. L. *J. Org. Chem.* **1992**, *57*, 2575–2585. (f) Stafford, J. A.; Heathcock, C. H. *J. Org. Chem.* **1990**, *55*, 5433–5434. (g) Ruggeri, R. B.; Hansen, M. M.; Heathcock, C. H. *J. Am. Chem. Soc.* **1988**, *110*, 8734–8736. (h) Heathcock, C. H.; Davidsen, S. K.; Mills, S.; Sanner, M. A. *J. Am. Chem. Soc.* **1986**, *108*, 5650–5651.
- (3) For a selection of recent approaches toward the synthesis of *Daphniphyllum* alkaloids other than daphnilactone B-type and yuzurimine-type, see: (a) Chattopadhyay, A. K.; Berger, G.; Hanessian, S. *J. Org. Chem.* **2016**, *81*, 5074–5086 and references cited therein. (b) Diaba, F.; Martínez-Laporta, A.; Coussanes, G.; Fernández, I.; Bonjoch, J. *Tetrahedron* **2015**, *71*, 3642–3651 and references cited therein. (c) Wang, W.; Li, G.-P.; Wang, S.-F.; Shi, Z.-F.; Cao, X.-P. *Chem.—Asian J.* **2015**, *10*, 377–382 and references cited therein. (d) Shvartsbart, A.; Smith, A. B., III *J. Am. Chem. Soc.* **2015**, *137*, 3510–3519. (e) Williams, D. R.; Mondal, P. K.; Bawel, S. A.; Nag, P. P. *Org. Lett.* **2014**, *16*, 1956–1959. (f) Yang, M.; Wang, L.; Wang, S.-H.; Zhang, S.-Y.; Tu, Y.-Q.; Zhang, F.-M.; He, Z.-H. *Org. Lett.* **2012**, *14*, 5114–5117. (g) Darses, B.; Michaelides, I. N.; Sladojevich, F.; Ward, J. W.; Rzepa, P. R.; Dixon, D. J. *Org. Lett.* **2012**, *14*, 1684–1687 and references cited therein.
- (4) (a) Denmark, S. E.; Baiazitov, R. Y. *J. Org. Chem.* **2006**, *71*, 593–605. (b) Denmark, S. E.; Baiazitov, R. Y.; Nguyen, S. T. *Tetrahedron* **2009**, *65*, 6535–6548. (c) Denmark, S. E.; Nguyen, S. T.; Baiazitov, R. Y. *Heterocycles* **2008**, *76*, 143–154.
- (5) Hayakawa, I.; Niida, K.; Kigoshi, H. *Chem. Commun.* **2015**, *51*, 11568–11571.
- (6) (a) Coldham, I.; Burrell, A. J. M.; Guerrand, H. D. S.; Oram, N. *Org. Lett.* **2011**, *13*, 1267–1269. (b) Coldham, I.; Watson, L.; Adams, H.; Martin, N. G. *J. Org. Chem.* **2011**, *76*, 2360–2366.
- (7) Hanessian, S.; Dorich, S.; Menz, H. *Org. Lett.* **2013**, *15*, 4134–4137.
- (8) Bélanger, G.; Boudreault, J.; Lévesque, F. *Org. Lett.* **2011**, *13*, 6204–6207.
- (9) (a) Lévesque, F.; Bélanger, G. *Org. Lett.* **2008**, *10*, 4939–4942. (b) Bélanger, G.; Darsigny, V.; Doré, M.; Lévesque, F. *Org. Lett.* **2010**, *12*, 1396–1399.
- (10) Kallury, K. R.; Krull, U. J.; Thompson, M. *J. Org. Chem.* **1988**, *53*, 1320–1322.
- (11) (a) Minami, I.; Nisar, M.; Yuhara, M.; Shimizu, I.; Tsuji, J. *Synthesis* **1987**, 992–998. (b) Yu, J.-Q.; Wu, H.-C.; Corey, E. J. *Org. Lett.* **2005**, *7*, 1415–1417.
- (12) (a) Lippert, A. R.; Kaeobamrung, J.; Bode, J. W. *J. Am. Chem. Soc.* **2006**, *128*, 14738–14739. The use of silyl acetal of *t*-butyl ester is known to limit Claisen condensation side products. See: (b) Okabay-

- shi, T.; Iida, A.; Takai, K.; Nawate, Y.; Misaki, T.; Tanabe, Y. *J. Org. Chem.* **2007**, *72*, 8142–8145.
- (13) Mukaiyama, T. *Angew. Chem., Int. Ed. Engl.* **1977**, *16*, 817–826.
- (14) Seven-membered rings are too flexible to rely on coupling constants in ^1H NMR or NOE experiments to assign relative stereochemistry.
- (15) Hergueta, A. R.; López, C.; Fernández, F.; Caamaño, O.; Blanco, J. M. *Tetrahedron: Asymmetry* **2003**, *14*, 3773–3778.
- (16) (a) Stork, G.; Wagle, S. S.; Mukharji, P. C. *J. Am. Chem. Soc.* **1953**, *75*, 3197–3204. (b) Peters, R. J.; Ravn, M. M.; Coates, R. M.; Croteau, R. B. *J. Am. Chem. Soc.* **2001**, *123*, 8974–8978.
- (17) (a) Pasqua, A. E.; Matheson, M.; Sewell, A. L.; Marquez, R. *Org. Process Res. Dev.* **2011**, *15*, 467–470. (b) Katritzky, A. R.; Chang, H.-X.; Yang, B. *Synthesis* **1995**, *1995*, 503–505.
- (18) Mayr, H.; Kempf, B.; Ofial, A. R. *Acc. Chem. Res.* **2003**, *36*, 66–77.
- (19) Pu, X.; Ma, D. *J. Org. Chem.* **2006**, *71*, 6562–6572.
- (20) Pelphrey, P. M.; Popov, V. M.; Joska, T. M.; Beierlein, J. M.; Bolstad, E. S. D.; Fillingham, Y. A.; Wright, D. L.; Anderson, A. C. *J. Med. Chem.* **2007**, *50*, 940–950.
- (21) Methyl enol ether **38** was also successfully tested in the Vilsmeier–Haack cyclization, but the resulting unstable oxycarbenium ion further reacted presumably in a Prins cyclization with the pendent alkene and led to a mixture of regioisomers.
- (22) Kitajima, M.; Takayama, H.; Sakai, S.-I. *J. Chem. Soc., Perkin Trans. 1* **1991**, 1773–1779.
- (23) Any attempt to deprotonate aldehyde **39** prior to silylation led to interference of the formamide and poor yields in desired compound **40**.
- (24) The use of a stabilized azomethine ylide ($Y = \text{CN}$ or CO_2Et , Scheme 1) leads to substitution β to nitrogen in the pyrrolidine ring, and subsequent steps would be required to cleave off the electron-withdrawing group.
- (25) Spino, C.; Joly, M.-A.; Godbout, C.; Arbour, M. *J. Org. Chem.* **2005**, *70*, 6118–6121.
- (26) Busch-Petersen, J.; Hill, W. A.; Fan, P.; Khanolkar, A.; Xie, X.-Q.; Tius, M. A.; Makriyannis, A. *J. Med. Chem.* **1996**, *39*, 3790–3796.
- (27) β effect of tin is about 10^4 more important than that of silicon. See: Hagen, G.; Mayr, H. *J. Am. Chem. Soc.* **1991**, *113*, 4954–4961.
- (28) A remarkable example of this is reported by Pearson. See: Pearson, W. H.; Dietz, A.; Stoy, P. *Org. Lett.* **2004**, *6*, 1005–1008.
- (29) Azomethine ylides are known to react faster with electron-deficient dipolarophiles. See ref 6.
- (30) Diastereocontrolled alkylation of five-membered rings is well-documented in the literature. See: (a) Hajra, S.; Mandal, A.; Hazra, S. *Tetrahedron Lett.* **2013**, *54*, 2171–2173. (b) Hajra, S.; Giri, A. K.; Hazra, S. *J. Org. Chem.* **2009**, *74*, 7978–7981.
- (31) Relative stereochemistry was secured by X-ray analysis of a crystallized derivative of one of the intermediate compounds in the 8-step sequence. See ref 8.
- (32) (a) Yinglin, H.; Hongwen, H. *Synthesis* **1990**, *1990*, 122–124. (b) Kantlehner, W. *Eur. J. Org. Chem.* **2003**, *2003*, 2530–2546.
- (33) Kulkarni, M. G.; Davawala, S. I.; Doke, A. K.; Pendharkar, D. S. *Synthesis* **2004**, 2919–2926.
- (34) Hanna, I.; Ricard, L. *Org. Lett.* **2000**, *2*, 2651–2654.
- (35) (a) Still, W. C.; Gennari, C. *Tetrahedron Lett.* **1983**, *24*, 4405–4408. (b) Nicolaou, K. C.; Yue, E. W.; la Greca, S.; Nadin, A.; Yang, Z.; Leresche, J. E.; Tsurii, T.; Naniwa, Y.; de Riccardis, F. *Chem.—Eur. J.* **1995**, *1*, 467–494.
- (36) Vedejs, E.; Grissom, J. W. *J. Org. Chem.* **1988**, *53*, 1876–1882.
- (37) Siebum, A. H. G.; Woo, W. S.; Lugtenburg, J. *Eur. J. Org. Chem.* **2003**, *2003*, 4664–4678.
- (38) *E-90* and *Z-90* both exist as a mixture of rotamers and were separated at this stage. However, due to the instability of the products, full characterization was not possible and both isomers were carried through the sequence separately. Only the sequence with the major isomer *E-90* is reported thereafter.
- (39) Guindon, Y.; Yoakim, C.; Morton, H. E. *Tetrahedron Lett.* **1983**, *24*, 2969–2972.
- (40) Integrity of the *Z- α,β* -unsaturated ester was preserved.
- (41) Roberts, S. W.; Rainier, J. D. *Org. Lett.* **2007**, *9*, 2227–2230.
- (42) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. *Org. Lett.* **1999**, *1*, 953–956.
- (43) In future work, installation of the cyclopentene ring will arise from functionalization of the cycloheptene. Regioselectivity will be key in this functionalization. If a discrimination between allylic positions based steric differentiation is not optimal, we also plan to use an aldehyde derivative as a directing group for regioselective functionalization of the alkene. All of these options will be judiciously incorporated into the aldehyde homologation and nitrile elimination/reduction sequence.
- (44) Friedrich, J.; Dolg, M.; Gansäuer, A.; Geich-Gimbel, D.; Lauterbach, T. *J. Am. Chem. Soc.* **2005**, *127*, 7071–7077.
- (45) Campbell, E. L.; Zuhl, A. M.; Liu, C. M.; Boger, D. L. *J. Am. Chem. Soc.* **2010**, *132*, 3009–3012.
- (46) Cocquet, G.; Rool, P.; Ferroud, C. *J. Chem. Soc., Perkin Trans. 1* **2000**, 2277–2281.
- (47) (a) Amat, M.; Gómez-Esqué, A.; Escolano, C.; Santos, M. M. M.; Molins, E.; Bosch, J. *J. Org. Chem.* **2009**, *74*, 1205–1211. (b) Cimarelli, C.; Palmieri, G. *J. Org. Chem.* **1996**, *61*, 5557–5563.
- (48) Maury, C.; Wang, Q.; Gharbaoui, T.; Chiadmi, M.; Tomas, A.; Royer, J.; Husson, H.-P. *Tetrahedron* **1997**, *53*, 3627–3636.
- (49) Agami, C.; Couty, F.; Evano, G.; Darro, F.; Kiss, R. *Eur. J. Org. Chem.* **2003**, *2003*, 2062–2070.
- (50) Nielsen, S. F.; Kharazmi, A.; Christensen, S. B. *Bioorg. Med. Chem.* **1998**, *6*, 937–945.
- (51) Santos, P. F.; Srinivasan, N.; Almeida, P. S.; Lobo, A. M.; Prabhakar, S. *Tetrahedron* **2005**, *61*, 9147–9156.
- (52) Relative stereochemistry at C10 was confirmed by NOESY experiment (see the SI) and is in agreement with the result obtained by Denmark with the hydrogenation of an exomethylene at C10 on a similar substrate. See ref 4b.
- (53) The excess of phenyldimethylsilylcuprate reacts with the excess of ethyl chloroformate to give ethyl phenyldimethylsilylcarboxylate as a side product. The latter could be separated from compound **30** with a careful flash chromatography, but could also be carried on to the next step. Saponification conditions give the corresponding phenyldimethylsilylanol that could be pumped off (b.p. 101–101.4 °C, 14 mm Hg) at 50 °C under high vacuum (ca. 0.01 mm Hg) over 6 h. See: Hyde, J. F.; Johansson, O. K.; Daudt, W. H.; Fleming, R. F.; Laudenslager, H. B.; Roche, M. P. *J. Am. Chem. Soc.* **1953**, *75*, 5615–5618.
- (54) The *Z* stereochemistry was assigned from a NOESY experiment with *Z-91* obtained by debenzoylation of compound *Z-90*.